

CURRICULUM VITAE UMBERTO VITOLO

Name: Umberto Vitolo

Place and date of birth: [REDACTED]

Education: Liceo Classico Massimo d'Azeglio, Torino from 1966 to 1971

Medical studies and postgraduated studies: Umberto Vitolo received his MD degree from the medical school of the University of Turin, Italy in 1977. Title of thesis: "Intereaction between Hb Hasharon and alfa-thalassemia: a model for the study of the structural alfa gene number in the Polesine population", marks 110/110 cum laude.

He was trained in Hematology at the University of Pavia, Italy from 1978 to 1980 and in Clinical Immunology at the University of Florence, Italy from 1983 to 1987.

Training: clinical research fellow at the section of Hematology/Oncology, department of Medicine and the Cancer Research Center, University of Chicago, USA from January 1984 to June 1984 and from September 1986 to December 1986.

Teaching: teacher of Immune-hematology at the school for professional nurses from 1984 to 1997. Teacher at the post-graduate seminars regarding lymphoproliferative disorders at the chair of Hematology, university of Bologna from 1999 till now.

Teacher at the post-graduate school of Haematology, University of Turin from 2001 to 2018.

Past Occupation: Assistent in Internal Medicine at the Emergency Department of the S. Giovanni Battista hospital of Torino from 1/4/80 to 31/9/81.

He worked as a staff member of the section of Hematology, Department of Oncology of San Giovanni Battista Hospital in Turin from 1981 to 1997.

Since 1997, he has been leading the clinical chemoimmunotherapy program for malignant lymphomas at the Department of Oncology, Section of Haematology, San Giovanni Battista Hospital in Turin, Italy. From April 2006 to November 2008 he was the director of chemoimmunotherapy lymphoma section at the Department of Oncology, San Giovanni Battista Hospital in Turin, Italy.

From December 22nd, 2008 to 30th November 2019 he was the Director of the Hematology section, Department of Oncology and Hematology, "Città della Salute e della Scienza" University-Hospital, Torino.

Present Occupation: Since 16th December 2019 he is hematology consultant at Candiolo Cancer Institute-Fondazione Piemontese per l'Oncologia-IRCCS, Candiolo (Torino), Italy. At Candiolo Cancer Institute he is the head for experimental clinical trials in hematology.

Scientific affiliations and appointments: he is member of

1. **The Italian Lymphoma Foundation** (formerly Italian Lymphoma Intergroup). From October 2007 to September 2010 he was the President of the Italian Lymphoma Intergroup. **Since October 2010 to November 2011 he was the president of the Italian Lymphoma Foundation. Actually, he is member of board of directors.**
2. **The Italian Society of Hematology.**
3. **The Italian Society of Experimental Hematology.**
4. **The American Society of Haematology.**
5. **The European Hematology Association.**

6. **The European Society of Medical Oncology.** In this society is a member of the **Faculty for haematological malignancies and participant to the development of follicular and diffuse large B-cell guidelines.**
7. Elected member of the **Accademy of Medicine in Torino, Italy**

International cooperations:

He is deeply involved in the activities of the **International Extranodal Lymphoma Study Group (IELSG)** (directed by Dr Cavalli and Dr Zucca) in which he was member of the board of directors from 2004 to 2007. Now he is involved in the IELSG in the development of clinical programs for extranodal lymphomas. He was the Principal Investigator of the IELSG 10 and IELSG 30 trials for Primary Testicular .

He is a member of the **European Mantle Cell Network** (directed by Dr Dreyling).

He was member of the steering committee that developed the **Follicular Lymphoma International Prognostic Index** in 2004

He has also been involved in many **international advisory boards** to discuss early results of international clinical trials

Scientific activities:

Dr Vitolo's research interests include haematological malignancies, chemotherapy and biological therapies and he has a special interest in the biology and treatment of malignant lymphoma.

He is member of the expert panel of the Italian Society of Hematology for the guide lines of the nodal and extranodal lymphomas. Dr Vitolo is a reviewer of several peer-reviewed scientific journals as Blood, Blood Advances, British Journal of Hematology, Annals of Oncology, Journal of Clinical Oncology, Leukemia and Lymphoma and others.

He has authored or co-authored many papers and abstracts in peer-reviewed journals.

Clinical Research:

He is actively involved in clinical research in malignant lymphoma and he is currently leading several cooperative multicenter trials in follicular and diffuse large cell lymphoma.

Scientific affiliations: member of the Italian Society of Hematology, the Italian Society of Experimental Hematology, the American Society of Haematology, the European Society of Medical Oncology. The European Haematology Association.

Papers

N° of papers in peer-review journals 309

PAPERS of di Umberto Vitolo

1. Camaschella C, Pich PG, Ciocca Vasino MA, David O, **Vitolo U**, Ricco G. L'Hb Hasharon come modello per lo studio dei geni alfa nella popolazione italiana del polesine. Atti del XXVI Congresso Nazionale della Società Italiana di Ematologia. Torino, 10-11 Giugno: 785-792, 1977.
2. Ricco G, Pich PG, **Vitolo U**, Ciocca Vasino MA. Identificazione di un nuovo gene strutturale (gamma T) per le gamma catene dell'emoglobina fetale umana. Giorn. Accad. Med Torino, vol CXLI: 76-77, 1978.
3. Paolino W, **Vitolo U**, I fattori timici linfocitotropi: la Timosina. *Minerva Endocrinologica* 5: 159-168, 1980.
4. Paolino W, Infelise V, A. Levis, Marmont F, **Vitolo U**, Paolino F, Rossi M, Jayme A, Remondino M. Adenosplenomegaly and prognosis in uncomplicated and complicated chronic lymphocytic leukemia. A study of 362 cases. *Cancer* 54: 339-346, 1984.
5. **Vitolo U**, Marmont F, Ciocca Vasino MA, Falda M, Genetta C, Caligaris Cappio F, Bergui L and Paolino W. T Acute Lymphoblastic Leukemia in Ataxia-Teleangiectasia. Report of a case characterized by monoclonal antibodies. *Haematologica* 69: 695-700, 1984.
6. Cornbleet MA, **Vitolo U**, Ultmann JE, Golomb HM, Oleske D, Griem M, Ferguson DJ, Miller JB. Pathologic stages IA and IIA Hodgkin's disease: results of treatment with Radiotherapy alone, 1968-1980. *J Clin Oncol* 3:758-768, 1985.
7. Mazza P, Bertini M, Mazza S, Lauria F, Pileri S, Rivano MT, Bacarani M, Ricci P, Fiacchini M, **Vitolo U**, Canta M, Paolino W, Zinzani PL, Poletti G, Verlicchi F, Gherlinzoni F, Tura S. Lymphoblastic Lymphoma in adolescents and adults. Clinical, pathological and prognostic evaluation. *Eur J Cancer Clin Oncol* 22:1503-10, 1986.
8. Levis A, **Vitolo U**, Ciocca Vasino MA, Degani GF, Cametti G, Bertini M, Jayme A e Resegotti L. Significato prognostico della risposta precoce alla chemioterapia nel morbo di Hodgkin in II e III stadio. Atti delle Sezioni Regionali S.I.E. (Supplemento di *Haematologica*) 1: 352-353, 1985.
9. Resegotti L, **Vitolo U**, Bertini M, Levis A, Cametti G, Canta M, Decrescenzo A. L'evoluzione dell'iter diagnostico e della strategia terapeutica nei NHL. Atti delle Sezioni Regionali S.I.E. (Supplemento di *Haematologica*) 2: 27-28, 1986.
10. **Vitolo U**, Bertini M, Levis A, Cametti G, Canta M, Urgesi A, Jayme A, Ciocca Vasino MA, Resegotti L. Fattori prognostici ed esperienza terapeutica nei NHL. Atti delle Sezioni Regionali S.I.E.(Supplemento di *Haematologica*) 2 : 29-31, 1986.
11. Bertini M, **Vitolo U**, Levis A, Canta M, Cametti G, Bosio C, Jayme A, Tonso A, Resegotti L. Presentazione clinica e staging nei NHL. Casistica personale. Atti delle Sezioni Regionali S.I.E. (Supplemento di *Haematologica*) 2: 32-34, 1986.
12. **Vitolo U**, Bertini M, Canta M, Levis A, Cametti G, Orsucci L, Resegotti L. I linfomi non-Hodgkin primitivi gastrointestinali: valutazione clinica ed esperienza terapeutica. *Sem Gastroenterol* 3: 91-93, 1987.
13. Levis A, **Vitolo U**, Ciocca Vasino MA, Cametti G, Urgesi A, Bertini M, Canta M, Monetti U, Bosio C, Jaime A, and Resegotti L. Predictive value of the Early Response to Chemotherapy in High-Risk stages II and III Hodgkin's disease. *Cancer* 60: 1713-1719, 1987.
14. Levis A, Cametti G, Pini M, Canta M, **Vitolo U**, Bertini M, Tonso A, Jayme A, Bosio C, Resegotti L. Localizzazione epatica del morbo di Hodgkin, validità predittiva degli esami biochimici e radiologici non invasivi. Atti delle Sezioni Regionali S.I.E. (Supplemento di *Haematologica*) 3: 121-122, 1987.
15. Canta M, Bertini M, **Vitolo U**, Bosio C, Cametti G, Levis A, Resegotti L. Valutazione clinica di 36 LNH gastrointestinali. Atti delle Sezioni Regionali S.I.E. (Supplemento di *Haematologica*) 3: 105-106, 1987.
16. Cametti G, Levis A, **Vitolo U**, Bertini M, Canta M, Orsucci L, Ciocca Vasino MA, Urgesi A, Monetti U, Rossi G, Resegotti L. Incidenza di gravi complicanze nella malattia di Hodgkin trattata con terapia combinata. Atti delle Sezioni Regionali S.I.E. (Supplemento di *Haematologica*) 3: 70-72, 1987.

17. Levis A, **Vitolo U**, Ciocca Vasino MA, Cametti G, Urgesi A, Bertini M, Canta M, Monetti U, Bosio C, Jayme A, Resegotti L. Predictive value of the early response to chemotherapy in high-risk stages II and III Hodgkin's disease. da: 'YEAR BOOK OF CANCER 1988' - Editor R.C. Hickey and G.F. Saunders - Year Book Medical Publisher, Inc : 212-214, 1988.
18. Brusamolino E, Bertini M, Guidi S, **Vitolo U**, Inverardi D, Merante S, Colombo A, Resegotti L, Rossi Ferrini P, Cametti G, Canta M, Bernasconi C. CHOP vs CNOP (N=Mitoxantrone) in Non-Hodgkin's Lymphoma, an interim report comparing efficacy and toxicity. *Haematologica* 73: 217-222, 1988.
19. Brusamolino E, Bertini M, Guidi S, **Vitolo U**, Castelli G, Inverardi D, Merante S, Colombo A, Cametti G, Canta M, Resegotti L, Rossi Ferrini P, Bernasconi C. Cyclophosphamide, Adriamycin, Vincristine and prednisone (CHOP) versus Cyclophosphamide, Mitoxantrone, Vincristine and Prednisone (CNOP) in stage II-IV non-Hodgkin's lymphoma: a phase III randomized study. *New Trends Ther Leuk Lymph* 3: 23-32, 1988.
20. Resegotti L, Bertini M, Tarella C, **Vitolo U**, Bertoncelli MC, Gallamini A, Gallo E, Gatti AM, Ghio R, Levis A, Luxi G, Marchi L, Novarino A, Novero D, Orlandi E, Orsucci L, Ricciuti F, Rota-Scalabrini D, Scassa E, Pileri A, Palestro G, Bernasconi C. Therapy with MACOP-B protocol for Diffuse Large Cell Lymphoma. Results of a cooperative study. Da *New Insights in lymphomas*. Editor Fondazione Gigi Ghirotti, Vicenza: 39-49, 1989.
21. **Vitolo U**, Bertini M, Tarella C, Bertoncelli MC, Gallamini A, Gallo E, Gatti AM, Ghio R, Levis A, Luxi G, Marchi L, Novarino A, Orlandi E, Orsucci L, Ricciuti F, Rota-Scalabrini D, Scassa E, Bernasconi C, Pileri A and Resegotti L. MACOP-B treatment for Advanced Stage Diffuse Large Cell Lymphoma: A Multicenter Italian Study. *Eur J Cancer Clin Oncol* 25: 1441-1449, 1989.
22. Levis A, Davini O, Garabello D, Urgesi A, **Vitolo U**, Bertini M, Depaoli L, Menduni T, Orsucci L, Foggetti MD, Resegotti L. Role of Thoracic computed tomography in the treatment plan of Hodgkin's disease. *Haematologica* 75:64-8, 1990.
23. Resegotti L, Barbui T, Bernasconi C, Perona G, Pileri A, Bertini M, Brusamolino E, Comotti B, Gallamini A, Gallo E, Ghio R, Levis A, Luxi G, Meneghini V, Orsucci L, Palestro G, Rota Scalabrini D, Tarella C, Todeschini G, Viero P, **Vitolo U**. La terapia dei linfomi diffusi a grandi cellule in stadio avanzato con il MACOP-B. Da *Progressi in Ematologia Clinica-Linfomi maligni non-Hodgkin* 90. Editore Bernasconi C, Casa editrice EMP: 197-211, 1990.
24. Levis A, Gavarotti P, Bazzan M, Ferrero D, Schinco PC, Marmont F, Paolino F, Ciocca Vasino MA, **Vitolo U**, Bertini M, Davini O, Urgesi A, Guerrasio A, Novarino A, Vineis P. Tempi di diagnosi e di stadiazione nei linfomi maligni. *Epidemiologia e prevenzione* 44: 43-45, 1990.
25. Resegotti L, **Vitolo U**, Bertini M, Brusamolino E, Comotti B, Tarella C, Todeschini G, Aglietta M, Barbui T, Bernasconi G, Ghio R, Perona G and Pileri A. MACOP-B for advanced stage large cell lymphoma (DLCL). More is better? *Leukemia* 5 (Suppl 1): 86-89, 1991.
26. **Vitolo U**, Orsucci L, Bertini M, Cavallero GB, Gallamini A, Ghio R, Levis A, Rota-Scalabrini D and Resegotti L. Mitoxantrone, Etoposide, Cisplatin and Dexamethasone (MEPD) as salvage chemotherapy in resistant non-Hodgkin's Lymphoma. *Haematologica* 76: 43-46, 1991.
27. Orsucci L, Bertini M, **Vitolo U**, Levis A, Depaoli L, Ficara F, De Crescenzo A, Resegotti L. Trattamento dei Linfomi non-Hodgkin a rischio intermedio ed alto localizzati con un programma di chemio-radioterapia. *Haematologica* 76 (Suppl 2): 125-127, 1991.
28. Depaoli L, **Vitolo U**, Bertini M, Levis A, Orsucci L, Ficara F, Ciocca vasino MA, Resegotti L. Esperienza clinica e terapeutica nei Linfomi non-Hodgkin primitivi del tratto gastrointestinale. *Haematologica* 76 (Suppl 2): 128-129, 1991.
29. Boggio Bertinet D, Pezzana A, **Vitolo U**, Bertini M, Xompero G, Palmo A e Balzola F. Supporto nutrizionale nel linfoma non-Hodgkin in trattamento con ciclo polichemioterapico MACOP-B. *Minerva Gastroenterol Dietol* 37: 117-21, 1991.

30. Bertini M, Orsucci L, **Vitolo U**, Levis A, Todeschini G, Meneghini V, Novero D, Tarella C, Gallo E, Luxi G, Pizzuti M, Novarino A, Urgesi A and Resegotti L. Stage II large B-cell lymphoma with sclerosis treated with MACOP-B. *Annals of Oncology* 2:733-737, 1991.
31. **Vitolo U**, Bertini M, Brusamolino E, Cavallero GB, Comotti B, Gallo E, Ghio R, Levis A, Luxi G, Meneghini V, Novero D, Orsucci L, Rota-Scalabrini D, Tarella C, Todeschini G, Viero P, Barbui T, Bernasconi C, Perona G, Pileri A, Resegotti L. MACOP-B treatment in diffuse large cell lymphoma: identification of prognostic groups in an italian multicenter study. *J Clin Oncol* 10: 219-227, 1992.
32. **Vitolo U**, Bertini M, Levis A, Orsucci L e Resegotti L. La terapia dei Linfomi Non-Hodgkin. *Acta Oncologica* 13: 603-614, 1992.
33. **Vitolo U**, Gerhartz H et al. The importance of dose intensity in lymphoma. *Oncology Review* 7 (n°4):19-20, 1992.
34. Bertini M, Freilone R, Levis A, Orsucci L, **Vitolo U**, Viero P, Todeschini G, Pini M, Tarella C, Pizzuti M, Marchi L, Salvi F, Secondo V, Volta C and Resegotti L. Linfomi non-Hodgkin nei pazienti anziani trattati con P-VEBEC: uno schema terapeutico a cadenza settimanale con utilizzo del fattore di crescita rG-CSF. *Geriatric & Medical Intelligence* 2: 64-69, 1993.
35. Bertini M, **Vitolo U**. Linfomi non-Hodgkin. In: Resegotti L ed. *Manuale di Terapia Medica*: 478-490, 1993.
36. Caracciolo D, Gavarotti P, Aglietta M, Bondesan P, Falda M, Gallo E, Locatelli F, Novarino A, Paolino F, Sanavio F, Urgesi A, **Vitolo U** and Tarella C. High-dose sequential (HDS) chemotherapy with blood and marrow cell autograft as salvage treatment in very poor prognosis, relapsed non-Hodgkin's lymphoma. *Bone Marrow Transplantation* 12: 621-625, 1993.
37. Freilone R, Bertini M, Orsucci L, **Vitolo U**, Novero D, Palestro G, Resegotti L. Valutazione prognostica nei Linfomi Intermedi F della Working Formulation. *Haematologica* 79 (Suppl 1): 92-94, 1994.
38. Ficara F, Levis A, Bertini M, Ricardi U, **Vitolo U**, Resegotti L. Confronto fra ABVD + Radioterapia e MOPP + Radioterapia nel morbo di Hodgkin in stadio II e III. *Haematologica* 79 (Suppl 1): 95-97, 1994.
39. Levis A, Depaoli L, Urgesi A, Bertini M, Orsucci L, **Vitolo U**, Buchi G, Gallamini A, Gavarotti P, Novarino A, Rota Scalabrini D, Mazza U, Pileri A, Sannazzari GL, Resegotti L. Probability of cure in elderly Hodgkin's disease patients. *Haematologica* 79: 46-54, 1994.
40. Resegotti L, Bertini M, **Vitolo U**. Linfomi non-Hodgkin. I manuali delle scuole, Frati L e Santi L eds: 1-101, 1994.
41. Bertini M, **Vitolo U**, Freilone R, Botto B, Pizzuti M, Gavarotti P, Levis A, Orlandi E, Orsucci L, Pini M, Rota-Scalabrini D, Salvi F, Secondo V, Todeschini G, Viero P, Volta C and Resegotti L. P-VEBEC: A new 8-weekly schedule with or without rG-CSF for elderly patients with aggressive non-Hodgkin's lymphoma (NHL). *Annals of Oncology* 5: 895-900, 1994.
42. Volpe G, **Vitolo U**, Carbone A, Pastore C, Bertini M, Botto B, Audisio E, Freilone R, Novero D, Cappia S, De Giuli P, Mazza U, Resegotti L, Palestro G, Saglio G and Gaidano G. Molecular Heterogeneity of B-Lineage Diffuse Large Cell Lymphoma. *Genes, Chromosomes & Cancer* 16:21-30, 1996.
43. Bertini M, Freilone R, **Vitolo U**, Botto B, Ciotti R, Cinieri S, Di Nota A, Di Vito F, Levis A, Orsucci L, Pini M, Rota-Scalabrini D, Todeschini G and Resegotti L. The treatment of elderly patients with aggressive Non-Hodgkin's Lymphomas: Feasibility and Efficacy of an Intensive Multidrug Regimen. *Leukemia and Lymphoma* 22: 483-493, 1996.
44. Levis A, Depaoli L, Bertini M, Botto B, Gallamini A, Gavarotti P, Ricardi U, Rota Scalabrini D, Salomone A, Salvi F, **Vitolo U**, Pileri A, Sannazzari GL and Resegotti L. Results of a low aggressive chemotherapy regimen (CVP/CEB) in elderly Hodgkin's disease patients. *Haematologica* 81:450-456, 1996.
45. Freilone R, Botto B, **Vitolo U**, Bertini M, Audisio E, Calvi R, Cucchi M, De Crescenzo A, Gallamini A, Ghio R, Griso R, Levis A, Massara G, Orsucci L, Ricardi U, Rota-Scalabrini D, Salvi F, Secondo V, Resegotti L.

- Combined modality treatment with a weekly brief chemotherapy (ACOP-B) followed by locoregional radiotherapy in localized-stage intermediate-to high-grade non-Hodgkin's lymphoma. *Annals of Oncology* 7: 919-924, 1996.
46. **Vitolo U.** HDS intensificata nei LDGC ad alto rischio. *Focus on* 5: 9-11, 1996.
 47. **Vitolo U,** Cortellazzo S, Liberati AM, Freilone R, Falda M, Bertini M, Botto B, Cinieri S, Levis A, Locatelli F, Lovisone E, Marmont F, Pizzuti M, Rossi A, Viero P, Barbui T, Grignani F and Resegotti L. Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma. *J Clin Oncol* 15:491-498, 1997.
 48. Bertini M, Freilone R, Botto B, Calvi R, Gallamini A, Gatti AM, Liberati AM, Meneghini V, Orlandi E, Orsucci L, Pizzuti M, Rota-Scalabrini D, Salvi F, Todeschini G, **Vitolo U** and Resegotti L. Idarubicin in patients with diffuse large cell lymphoma: a randomized trial comparing VACOP-B (A= Doxorubicin) vs VICOP-B (I=Idarubicin). *Haematologica* 82: 309-313, 1997.
 49. Bertini M, Freilone R, **Vitolo U,** Botto B, Ciotti R, Cinieri S, Di Nota A, Di Vito F, Levis A, Orsucci L, Pini M, Rota Scalabrini D and Resegotti L. The treatment of elderly patients with aggressive non-Hodgkin's lymphoma: feasibility and efficacy of an intensive multidrug regimen. *Biotherapy in Cancer* 1(2): 38-41, 1997.
 50. **Vitolo U.** Terapia ad alte dosi con autotrapianto e terapia convenzionale intensificata nei linfomi aggressivi. *Focus on* 6: 24, 1998.
 51. Kalachilov S, Migliazza A, Cayanis E, Fracchiola NS, Bonaldo MF, Lawton L, Jelenc P, Ye X, Qu X, Chien M, Hauptschein R, Gaidano G, **Vitolo U,** Saglio G, Resegotti L, Brojiansky V, Yankovsky, Zhang P, Soares MB, Russo J, Edelman IS, Efstratiadis A, Dalla-Favera R and Fisher SG. Cloning and Gene Mapping of the Chromosome 13q14 region deleted in Chronic Lymphocytic Leukemia. *Genomics* 42: 369-377, 1997.
 52. Bertini M, Rus C, Freilone R, Botto B, Calvi R, Novero D, Orsucci L, **Vitolo U,** Palestro G and Resegotti L. Mantle cell lymphoma: a retrospective study on 27 patients. Clinical features and natural history. *Haematologica* 83: 312-316, 1998.
 53. **Vitolo U,** Gaidano G, Botto B, Volpe G, Audisio E, Bertini M, Calvi R, Freilone R, Novero D, Orsucci L, Pastore C, Capello D, Parvis G, Sacco C, Zagonel V, Carbone A, Mazza U, Palestro G, Saglio G and Resegotti L. Rearrangements of BCL6, BCL2, c-MYC and 6 q deletion in B-Cell Lymphoma: Clinical relevance in 71 patients. *Ann Oncol* 9: 1-7, 1998.
 54. **Vitolo U,** Boccomini C, Pregno P. Il Melphalan ad alte dosi. Cap IV in "Farmaci antitumorali ad alte dosi". Eds Bumma C e Airolidi M vol 1: 95-119, 1998.
 55. Calvi R, Bertini M, Boccomini C, Botto B, Orsucci L, **Vitolo U.** Burkitt's lymphomas in adults: retrospective analysis of 30 cases treated with two different schemes. *Haematologica* 1999 Apr; 84(4):383-4.
 56. Gallo E, Pregno P, Allione B, **Vitolo U.** Malattie del sangue e degli organi emopoietici. In Moiraghi P: La nuova patologia medica e infermieristica clinica. C.G. Edizioni Medico Scientifiche, Torino 1999; 37-86.
 57. Tarella C, Corradini P, Astolfi M, Bondesan P, Caracciolo D, Cherasco C, Ladetto M, Giaretta F, Ricca I, **Vitolo U,** Pileri A, Ferrero D. Negative immunomagnetic ex vivo purging combined with high-dose chemotherapy with peripheral blood progenitor cell autograft in follicular lymphoma patients: evidence for long-term clinical and molecular remissions. *Leukemia* 1999 Sep; 13(9):1456-62.
 58. Cortelazzo S, Rossi A, Roggero F, Oldani E, Zucca E, Tondini C, Ambrosetti A, Pasini F, Pinotti G, Bertini M, **Vitolo U,** Busetto M, Gianni L, Cavalli F, Barbui T. Stage-modified international prognostic index effectively predicts clinical outcome of localized primary gastric diffuse large B-cell lymphoma. International Extranodal Lymphoma Study Group. *Ann Oncol* 1999 Dec; 10(12):1433-40.
 59. Capello D, **Vitolo U,** Pasqualucci L, Quattrone S, Migliaretti G, Fassone L, Ariatti C, Vivenza D, Gloghini A, Pastore C, Lanza C, Nomdedeu J, Botto B, Freilone R, Buonaiuto D, Zagonel V, Gallo E, Palestro G, Saglio G,

- Dalla-Favera R, Carbone A, Gaidano G. Distribution and pattern of BCL-6 mutations throughout the spectrum of B-cell neoplasia. *Blood* 2000 Jan 15; 95(2):651-9.
60. Federico M, **Vitolo U**, Zinzani PL, Chisesi T, Clo V, Bellesi G, Magagnoli M, Liberati M, Boccomini C, Niscola P, Pavone V, Cuneo A, Santini G, Brugiattelli M, Baldini L, Rigacci L, Resegotti L. Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. *Intergruppo Italiano Linfomi. Blood* 2000 Feb 1; 95(3):783-9.
 61. Lomater C, Boccomini C, **Vitolo U**, Genetta C, Modena V. Successful treatment of neutropenia due to T-large granular lymphocytes leukemia associated with rheumatoid arthritis by long term administration of granulocyte stimulating factor (G-CSF). *Reumatismo* 2000; 52, 1/2: 49-53.
 62. Migliazza A, Cayanis E, Bosch-Albareda F, Komatsu H, Martinotti S, Toniato E, Kalachikov S, Bonaldo MF, Jelenc P, Ye X, Rzhetsky A, Qu X, Chien M, Inghirami G, Gaidano G, **Vitolo U**, Saglio G, Resegotti L, Zhang P, Soares MB, Russo J, Fischer SG, Edelman IS, Efstradiatis A, Dalla-Favera R. Molecular Pathogenesis of B-Cell Chronic Lymphocytic Leukemia: Analysis Of 13q14 Chromosomal Deletions. *Curr Top Microbiol Immunol* 2000; 252:275-284.
 63. Cortellazzo S, Rambaldi A, Rossi A, Oldani E, Ghielmini M, Benedetti F, Tarella C, Zaglio F, **Vitolo U**, Di Nicola M, Pogliani E, Cavalli F, Gianni AM, Barbui T. Intensification of salvage treatment with high-dose sequential chemotherapy improves the outcome of patients with refractory or relapsed aggressive non-Hodgkin's lymphoma. *Br J Haematol.* 2001 Aug;114(2):333-41.
 64. Guglielmi C, Martelli M, Federico M, Zinzani PL, **Vitolo U**, Bellesi G, Santini G, Tarella C, Zallio F, Pregno P, Di Renzo N, Resegotti L. Risk-assessment in diffuse large cell lymphoma at first relapse. A study by the Italian Intergroup for Lymphomas. *Haematologica.* 2001 Sep;86(9):941-50.
 65. Sacchi S, Federico M, **Vitolo U**, Boccomini C, Vallisa D, Baldini L, Petrini M, Rupoli S, Di Raimondo F, Merli F, Liso V, Tabilio A, Saglio G, Vinci G, Brugiattelli M, Dastoli G. Clinical activity and safety of combination immunotherapy with IFN-alpha 2a and Rituximab in patients with relapsed low grade non-Hodgkin's lymphoma. *Haematologica.* 2001 Sep;86(9):951-8.
 66. Ladetto M, Zallio F, Vallet S, Ricca I, Cuttica A, Caracciolo D, Corradini P, Astolfi M, Sametti S, Volpato F, Bondesan P, Vitolo U, Boccadoro M, Pileri A, Gianni AM, Tarella C. Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma. *Leukemia.* 2001 Dec;15(12):1941-9.
 67. Esteller M, Gaidano G, Goodman SN, Zagonel V, Capello D, Botto B, Rossi D, Gloghini A, Vitolo U, Carbone A, Baylin SB, Herman JG. Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma. *J Natl Cancer Inst.* 2002 Jan 2;94(1):26-32.
 68. **Vitolo U**, Botto B, Capello D, Vivenza D, Zagonel V, Gloghini A, Novero D, Parvis G, Calvi R, Ariatti C, Milan I, Bertini M, Boccomini C, Freilone R, Pregno P, Orsucci L, Palestro G, Saglio G, Carbone A, Gallo E, Gaidano G. Point mutations of the BCL-6 gene: clinical and prognostic correlation in B-diffuse large cell lymphoma. *Leukemia.* 2002 Feb;16(2):268-75.
 69. Nardini E, Rizzi S, Capello D, **Vitolo U**, Gaidano G, Menard S, Balsari A. Most immunoglobulin heavy chain switch mu rearrangements in B-cell chronic lymphocytic leukemia are internal deletions. *FEBS Lett.* 2002 May 8;518(1-3):119-23.
 70. Ladetto M, Corradini P, Vallet S, Benedetti F, **Vitolo U**, Martelli M, Brugiattelli M, Coser P, Pernotti A, Majolino I, Fioritoni G, Morandi S, Musso M, Zambrello R, Chisesi T, Di Renzo N, Vivaldi P, De Crescenzo A, Gallamini A, Salvi F, Santini G, Boccomini C, Sorio M, Astolfi M, Drandi D, Pileri A, Tarella C. High rates of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential

chemotherapy and autografting at diagnosis: a multicentre, prospective study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO). *Blood* 2002; 100 (5): 1559-65.

71. Zucca E, Conconi A, Mughal TI, Sarris AH, Seymour JF, **Vitolo U**, Klasa R, Ozsahin M, Mead GM, Gianni MA, Cortelazzo S, Ferreri AJ, Ambrosetti A, Martelli M, Thieblemont C, Moreno HG, Pinotti G, Martinelli G, Mozzana R, Grisanti S, Provencio M, Balzarotti M, Laveder F, Oltean G, Callea V, Roy P, Cavalli F, Gospodarowicz MK; International Extranodal Lymphoma Study Group. Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. *J Clin Oncol.* 2003 Jan 1;21(1):20-7.
72. Tarella C, Cuttica A, **Vitolo U**, Liberati M, Di Nicola M, Cortelazzo S, Rosato R, Rosanelli C, Di Renzo N, Musso M, Pavone E, Santini G, Pescarollo A, De Crescenzo A, Federico M, Gallamini A, Pregno P, Romano R, Coser P, Gallo E, Boccadoro M, Barbui T, Pileri A, Gianni AM and Levis. A high-dose sequential chemotherapy and peripheral blood progenitor cell (PBPC) autografting in refractory/relapsed Hodgkin's lymphoma: a multicenter study of the intergruppo italiano linfomi (IIL) showing prolonged disease-free survival in patients treated at first relapse. *Cancer* 2003, Jun 1;97(11):2748-59.
73. Ladetto M, Mantoan B, Ricca I, Astolfi M, Drandi D, Compagno M, Vallet S, dell'Aquila M, Alfarano A, Rossatto P, Rocci A, **Vitolo U**, Corradini P, Boccadoro M, Tarella C. Recurrence of Bcl-2/IgH polymerase chain reaction positivity following a prolonged molecular remission can be unrelated to the original follicular lymphoma clone. *Exp Hematol.* 2003 Sep;31(9):784-8.
74. Rigacci L, Federico M, Martelli M, Zinzani PL, Cavanna L, Bellesi G, Merli F, Alterini R, Petrucci MT, Tani M, Liberati AM, **Vitolo U**, Pavone V, Cuneo A, Chisesib T, Brugiattelli M; Intergruppo Italiano Linfomi. The role of anthracyclines in combination chemotherapy for the treatment of follicular lymphoma: retrospective study of the Intergruppo Italiano Linfomi on 761 cases. *Leuk Lymphoma.* 2003 Nov;44(11):1911-7.
75. Nardini E, Neri F, Vicenzi E, Poli G, Capello D, Gaidano G, **Vitolo U**, Menard S, Balsari A. Thymic function and immunoglobulin mutation genotype in B-cell chronic lymphocytic leukemia patients. *Int J Cancer.* 2003 Dec 20;107(6):958-61.
76. Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, **Vitolo U**, Morabito F, Martelli M, Brusamolino E, Iannitto E, Zaja F, Cortelazzo S, Rigacci L, Devizzi L, Todeschini G, Santini G, Brugiattelli M, Federico M; Intergruppo Italiano Linfomi. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. *Blood.* 2004 Apr 1;103(7):2474-9.
77. Levis A, Anselmo AP, Ambrosetti A, Adamo F, Bertini M, Cavalieri E, Gavarotti P, Genua A, Liberati M, Pavone V, Pietrasanta D, Ricetti MM, Scalabrini DR, Salvi F, **Vitolo U**, Angelucci E, Boccadoro M, Gallo E, Mandelli F; Intergruppo Italiano Linfomi (IIL) study. VEPEMB in elderly Hodgkin's lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study. *Ann Oncol.* 2004 Jan;15(1):123-8.
78. Todeschini G, Secchi S, Morra E, **Vitolo U**, Orlandi E, Pasini F, Gallo E, Ambrosetti A, Tecchio C, Tarella C, Gabbas A, Gallamini A, Gargantini L, Pizzuti M, Fioritoni G, Gottin L, Rossi G, Lazzarino M, Menestrina F, Paulli M, Palestro M, Cabras MG, Di Vito F, Pizzolo G. Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B. *Br J Cancer.* 2004 Jan 26;90(2):372-6.
79. Rossi D, Capello D, Gloghini A, Franceschetti S, Paulli M, Bhatia K, Saglio G, **Vitolo U**, Pileri SA, Esteller M, Carbone A, Gaidano G. Aberrant promoter methylation of multiple genes throughout the clinico-pathologic spectrum of B-cell neoplasia. *Haematologica.* 2004 Feb;89(2):154-64.
80. Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, Au WY, Bellei M, Brice P, Caballero D, Coiffier B, Conde Garcia E, Doyen C, Federico M, Fisher RI, Garcia-Conde JF, Guglielmi C, Hagenbeek A, Haioun C, LeBlanc M, Lister AT, Lopez-Guillermo A, Mc Laughlin P, Milpied N, Morel P, Mounier N, Proctor SJ, Rohatiner A, Smith P, Soubeyran P, Tilly H, **Vitolo U**, Zinzani PL, Zucca E, Montserrat E. Follicular lymphoma international prognostic index. *Blood.* 2004;104:1258-1265.
81. Levis A, Pietrasanta D, Godio L, **Vitolo U**, Ciravegna G, Di Vito F, Gavarotti P, Guglielmelli T, Orsucci L, Raviol E, Rota Scalabrini D, Salvi F, Tonso A, Aglietta M, Boccadoro M, Gallamini A, Saglio G, Scassa E,

- Gallo E. A large scale study of Bone Marrow Involvement in patients with Hodgkin's Lymphoma. *Clinical Lymphoma*. 2004; 5: 50-55.
82. P. Berto, A. Morsanutto, S. Lopatriello, M. Martelli, G. Muti, G. Santini, **U. Vitolo**. Analisi costo-efficacia di rituximab + CHOP *versus* CHOP in soggetti affetti da linfoma non-Hodgkin aggressivo *PharmacoEconomics - Italian Research Articles* 6 (3): 151-160, 2004.
 83. Morabito F, Gallamini A, Stelitano C, Callea V, Guglielmi C, Neri S, Lazzaro A, Orsucci L, Ilariucci F, Sacchi S, **Vitolo U**, Federico M. Clinical relevance of immunophenotype in a retrospective comparative study of 297 peripheral T-cell lymphomas, unspecified, and 496 diffuse large B-cell lymphomas: experience of the Intergruppo Italiano Linfomi. *Cancer*. 2004 Oct 1;101(7):1601-8.
 84. **Vitolo U**, Liberati AM, Cabras MG, Federico M, Angelucci E, Baldini L, Boccomini C, Brugiattelli M, Calvi R, Ciccone G, Genua A, Lambertenghi Delilieri G, Levis A, Parvis G, Pavone E, Salvi F, Sborgia M, Gallo E on behalf of the Intergruppo Italiano Linfomi. High dose sequential chemotherapy with autologous transplantation versus dose-dense chemotherapy MegaCEOP as first line treatment in poor-prognosis diffuse large cell lymphoma: an "Intergruppo Italiano Linfomi" randomized trial. *Haematologica*. 2005 Jun; 90(6):793-801.
 85. Manazza AD, Bonello L, Pagano M, Chiusa L, Novero D, Stacchini A, Martini G, **Vitolo U**, Tarella C, Inghirami G, Palestro G, Chiarle R. Follicular origin of a subset of CD5+ diffuse large B-cell lymphomas. *Am J Clin Pathol*. 2005 Aug;124(2):182-90.
 86. Barosi G, Carella A, Lazzarino M, Marchetti M, Martelli M, Rambaldi A, Tarella C, **Vitolo U**, Zinzani PL, Tura S. Management of nodal indolent (non marginal-zone) non-Hodgkin's lymphomas: practice guidelines from the Italian Society of Hematology, Italian Society of Experimental Hematology and Italian Group for Bone Marrow Transplantation. *Haematologica*. 2005 Sep;90(9):1236-57.
 87. Gobbi PG, Levis A, Chisesi T, Broglia C, **Vitolo U**, Stelitano C, Pavone V, Cavanna L, Santini G, Merli F, Liberati M, Baldini L, Lambertenghi Delilieri G, Angelucci E, Bordonaro R, Federico M. ABVD Versus Modified Stanford V Versus MOPPEBVCAD With Optional and Limited Radiotherapy in Intermediate- and Advanced-Stage Hodgkin's Lymphoma: Final Results of a Multicenter Randomized Trial by the Intergruppo Italiano Linfomi. *J Clin Oncol*. 2005 Dec 20;23(36):9198-207
 88. Barosi G, Carella A, Lazzarino M, Marchetti M, Martelli M, Rambaldi A, Tarella C, **Vitolo U**, Zinzani PL, Tura S. Management of nodal diffuse large B-cell lymphomas: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. *Haematologica*. 2006 Jan;91(1):96-103.
 89. Pavone V, Gaudio F, Console G, **Vitolo U**, Iacopino P, Guarini A, Liso V. Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation. *Bone Marrow Transplant*. 2006 Apr;37(8):719-24.
 90. Hagenbeek A, Eghbali H, Monfardini S, **Vitolo U**, Hoskin PJ, de Wolf-Peeters C, MacLennan K, Staab-Renner E, Kalmus J, Schott A, Teodorovic I, Negrouk A, van Glabbeke M, Marcus R. Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant Non-Hodgkin's lymphoma. *J Clin Oncol*. 2006 Apr 1;24(10):1590-6.
 91. **Vitolo U**. Dose-dense chemotherapy and prevention of neutropenia in diffuse large B-cell and Hodgkin's lymphoma. *Haematologica*. 2006 Apr;91(4):437.
 92. Gallamini A, Rigacci L, Merli F, Nassi L, Bosi A, Capodanno I, Luminari S, **Vitolo U**, Sancetta R, Iannitto E, Trentin L, Stelitano C, Tavera S, Biggi A, Castagnoli A, Versari A, Gregianin M, Pelosi E, Torchio P, Levis A. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. *Haematologica*. 2006 Apr;91(4):475-81.

93. **Vitolo U**, Chiappella A, Rossi G, Angelucci E, Liberati M, Gallo E. The effect of adding Rituximab to high dose chemotherapy. *Haematologica reports*. 2006 May;2(7):77-80.
94. Ladetto M, Vallet S, Benedetti F, **Vitolo U**, Martelli M, Callea V, Patti C, Coser P, Perrotti A, Sorio M, Boccomini C, Pulsioni A, Stelitano C, Scime R, Boccadoro M, Rosato R, De Marco F, Zanni M, Corradini P, Tarella C. Prolonged survival and low incidence of late toxic sequelae in advanced follicular lymphoma treated with a TBI-free autografting program: updated results of the multicenter consecutive GITMO trial. *Leukemia*. 2006 Oct;20(10):1840-7.
95. Chiappella A e **Vitolo U**. Macroglobulinemia di Waldenstrom. In Morra E e Molteni A: *Casi Clinici in Onco-ematologia*. Pensiero Scientifico Editore, Roma 2006; 141-147.
96. Chiappella A e **Vitolo U**. Linfoma non-Hodgkin follicolare: “watch and wait” e scelta di terapia di prima linea. In Morra E e Molteni A: *Casi Clinici in Onco-ematologia*. Pensiero Scientifico Editore, Roma 2006; 156-162.
97. Chiappella A e **Vitolo U**. Linfoma non-Hodgkin follicolare: Chemioterapia ad alte dosi e autologo nella recidiva. In Morra E e Molteni A: *Casi Clinici in Onco-ematologia*. Pensiero Scientifico Editore, Roma 2006; 163-169.
98. Chiappella A e **Vitolo U**. Linfoma non-Hodgkin follicolare: ruolo del mantenimento con Rituximab dopo terapia di prima linea. In Morra E e Molteni A: *Casi Clinici in Onco-ematologia*. Pensiero Scientifico Editore, Roma 2006; 170-175.
99. Chiappella A e **Vitolo U**. Linfoma marginale splenico. In Morra E e Molteni A: *Casi Clinici in Onco-ematologia*. Pensiero Scientifico Editore, Roma 2006; 176-182.
100. Merli F, Bertini M, Luminari S, Mozzana R, Botto B, Liberati AM, Baldini L, Cabrsa G, Di Vito F, Orsucci L, Naglieri E, Polimeno G, Marcheselli L, Pennese E, **Vitolo U**, Federico M, Gallo E. Long term results of a randomized study performed by Intergruppo Italiano Linfomi comparing MiniCEOP vs P-VEBEC in elderly patients with diffuse large B-cell lymphoma. *Leuk Lymphoma*. 2007 Feb;48(2):367-7
101. Greb A, Bohlius J, Trelle S, Schiefer D, De Souza CA, Gisselbrecht C, Intragumtornchai T, Kaiser U, Kluijn-Nelemans HC, Martelli M, Milpied NJ, Santini G, Verdonck LF, **Vitolo U**, Schwarzer G, Engert A. High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma - Results of a comprehensive meta-analysis. *Cancer Treat Rev*. 2007 Jun;33(4):338-46.
102. Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, Patti C, Loft A, Di Raimondo F, D'Amore F, Biggi A, **Vitolo U**, Stelitano C, Sancetta R, Trentin L, Luminari S, Iannitto E, Viviani S, Pierri I, Levis A. Early interim 2-(18)fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. *J Clin Oncol*. 2007 Aug 20;25(24):3746-52.
103. Rigacci L, **Vitolo U**, Nassi L, et al. Positron emission tomography in the staging of patients with Hodgkin's Lymphoma. A prospective multicentric study by the Intergruppo Italiano Linfomi. *Ann Hematol*. 2007 Dec;86(12):897-903.
104. Zinzani PL, Tani M, Fanti S, Stefoni V, Musuraca G, **Vitolo U**, Perrotti A, Fina M, Derenzini E, Baccarani M. A phase 2I trial of Fludarabine and Mitoxantrone chemotherapy followed by Yttrium90 ibritumomab tiuxetan for patients with previously untreated, indolent non-follicular non-Hodgkin's lymphoma. *Cancer*. 2008 Feb 15;112(4):856-62.
105. **Vitolo U**, Ferreri AJ, Zucca E. Primary testicular lymphoma. *Crit Rev Oncol Hematol*. 2008 Feb;65(2):183-9.
106. **Vitolo U**, Ferreri AJ, Montoto S. Follicular lymphomas. *Crit Rev Oncol Hematol*. 2008 Mar 20; [Epub ahead of print]

107. Pelosi E, Penna D, Deandreis D, Chiappella A, Skanjeti A, **Vitolo U**, Bisi G. FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management. *Q J Nucl Med Mol Imaging*. 2008 Mar;52(1):9-16.
108. Brusamolino E, Maffioli M, Bonfichi M, **Vitolo U**. Front-line therapy for nonlocalized diffuse large B-cell lymphoma: what has been demonstrated and what is yet to be established. *Future Oncol* 2008 Apr; 4(2): 199-210
109. Ladetto M, De Marco F, Benedetti F, **Vitolo U**, et al. Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an over-all survival advantage. *Blood*. 2008 April 15; 111: 4004-4013.
110. Pelosi E, Pregno P, Penna D, Deandreis D, Chiappella A, Limerutti G, **Vitolo U**, Mancini M, Bisi G, Gallo E. Role of whole-body (18)F fluorodeoxyglucose positron emission tomography/computer tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma. *Radiol Med* 2008 Jun;113(4):578-90.
111. **Vitolo U**, Ferreri AJM, Montoto S. Lymphoplasmacytic Lymphoma – Waldenstrom's Macroglobulinemia. *Crit Rev Oncol Hematol*. 2008 Aug;67(2):172-85.
112. Zinzani PL, Martelli M, Poletti V, **Vitolo U**, Gobbi PG, Chisesi T, Barosi G, Ferreri AJ, Marchetti M, Pimpinelli N, Tura S; Practice guidelines for the management of extranodal non-Hodgkin's lymphomas of adult non-immunodeficient patients. Part I: primary lung and mediastinal lymphomas. A project of the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. *Haematologica*. 2008 Sep;93(9):1364-71.
113. Morschhauser F, Radford J, Van Hoof A, **Vitolo U**, Soubeyran P, Tilly H, Huijgens PC, Kolstad A, d'Amore F, Gonzalez Diaz M, Petrini M, Sebban C, Zinzani PL, van Oers MH, van Putten W, Bischof-Delaloye A, Rohatiner A, Salles G, Kuhlmann J, Hagenbeek A. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. *J Clin Oncol*. 2008 Nov 10;26(32):5156-64.
114. **Vitolo U**, Zucca E and Seymour JF. Primary Testicular Lymphoma. In: Cavalli F, Stein H, Zucca E eds. *Extranodal Lymphomas, Pathology and management*. Informa Healthcare 2008.
115. Hancock BW, Qian W, Linch D, Delchier JC, Smith P, Jakupovic I, Burton C, Souhami R, Wotherspoon A, Copie-Bergman C, Capella C, Traulle C, Levy M, Cortelazzo S, Ferreri AJ, Ambrosetti A, Pinotti G, Martinelli G, **Vitolo U**, Cavalli F, Gisselbrecht C, Zucca E. Chlorambucil versus observation after anti-Helicobacter therapy in gastric MALT lymphomas: results of the international randomised LY03 trial. *Br J Haematol*. 2009 Feb;144(3):367-75
116. Rossi D, Rasi S, Franceschetti S, Capello D, Castelli A, De Paoli L, Ramponi A, Chiappella A, Pogliani EM, **Vitolo U**, Kwee I, Bertoni F, Conconi A, Gaidano G. Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21. *Leukemia*. 2009 Jun;23(6):1118-26.
117. Cabras MG, Mamusa AM, **Vitolo U**, Freilone R R, Dessalvi P, Orsucci L, Tonso A, Levis A, Liberati M, Lay G, Angelucci E. Long term outcome of localized aggressive non-Hodgkin lymphoma treated with a short weekly chemotherapy regimen (doxorubicin, cyclophosphamide, bleomycin, vincristine, and prednisone) and involved field radiotherapy: result of a Gruppo Italiano Multiregionale per lo Studio dei Linfomi e Leucemie (GIMURELL) study. *Leuk Lymphoma*. 2009 Sep;50(9):1475-81
118. **Vitolo U**, Chiappella A, Angelucci E, Rossi G, Liberati AM, Cabras MG, Botto B, Ciccone G, Gaidano G, Falchi L, Freilone R, Novero D, Orsucci L, Pavone V, Pogliani E, Rota-Scalabrini D, Salvi F, Tonso A, Tucci A, Levis A; on behalf of Gruppo Italiano Multiregionale Linfomi e Leucemie (GIMURELL). Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study. *Haematologica*. 2009 Sep;94(9):1250-8.

119. Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, **Vitolo U**, Pro B, Pileri S, Pulsoni A, Soubeyran P, Cortelazzo S, Martinelli G, Martelli M, Rigacci L, Arcaini L, Di Raimondo F, Merli F, Sabattini E, McLaughlin P, Solal-Céligny P. Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project. *J Clin Oncol.* 2009 Sep 20;27(27):4555-62.
120. **Vitolo U**, Barosi G, Fanti S, Gianni AM, Martelli M, Petrini M, Zinzani PL, Tura S. Consensus conference on the use of 90-yttrium-ibritumomab tiuxetan therapy in clinical practice. A project of the Italian society of hematology. *Am J Hematol.* 2010 Feb;85(2):147-55.
121. Morschhauser F, Marlton P, **Vitolo U**, Lindén O, Seymour JF, Crump M, Coiffier B, Foà R, Wassner E, Burger HU, Brennan B, Mendila M. Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma. *Ann Oncol.* 2010 Sep;21(9):1870-6.
122. **Vitolo U**, Chiappella A, Frairia C and Botto B. The treatment of Diffuse Large B-cell Lymphoma with poor prognosis in the Rituximab Era – State of the Art and future perspectives. *European Haematology.* 2010. Vol 2, Issue 1.
123. Rigacci L, Fabbri A, Puccini B, Chitarrelli I, Chiappella A, **Vitolo U**, Levis A, Lauria F, Bosi A. Oxaliplatin-based chemotherapy (dexamethasone, high-dose cytarabine, and oxaliplatin)±rituximab is an effective salvage regimen in patients with relapsed or refractory lymphoma. *Cancer.* 2010 Oct 1;116(19):4573-9.
124. Squadrone V, Massaia M, Bruno B, Marmont F, Falda M, Bagna C, Bertone S, Filippini C, Slutsky AS, **Vitolo U**, Boccadoro M, Ranieri VM. Early CPAP prevents evolution of acute lung injury in patients with hematologic malignancy. *Intensive Care Med.* 2010 Oct;36(10):1666-74
125. Conconi A, Martinelli G, Lopez-Guillermo A, Zinzani PL, Ferreri AJ, Rigacci L, Devizzi L, **Vitolo U**, Luminari S, Cavalli F, Zucca E. Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG). *Ann Oncol.* 2011 Mar; 22(3):689-95.
126. Benevolo G, Larocca A, Gentile M, Pregno P, Gay F, Botto B, Frairia C, Evangelista A, Morabito F, Boccadoro M, **Vitolo U**, Palumbo A. The efficacy and safety of bortezomib and dexamethasone as a maintenance therapy in patients with advanced multiple myeloma who are responsive to salvage bortezomib-containing regimens. *Cancer.* 2011 May 1;117(9):1884-90.
127. Rossi D, Rasi S, Di Rocco A, Fabbri A, Forconi F, Gloghini A, Brusca A, Franceschetti S, Fangazio M, De Paoli L, Bruna R, Capello D, Chiappella A, Lobetti Bodoni C, Giachelia M, Tisi MC, Pogliani EM, Lauria F, Ladetto M, Hohaus S, Martelli M, **Vitolo U**, Carbone A, Foà R, Gaidano G. The host genetic background of DNA repair mechanisms is an independent predictor of survival in diffuse large B-cell lymphoma. *Blood* 2011; Feb 24;117(8):2405-13.
128. Chiappella A, Ciochetto C, Orsucci L, **Vitolo U**. Update in indolent non-Hodgkin lymphoma (NHL): paradigm for Waldenström's macroglobulinemia (WM). *Clin Lymphoma Myeloma Leuk.* 2011 Feb;11(1):149-51.
129. **Vitolo U**, Chiappella A, Ferreri AJ, Martelli M, Baldi I, Balzarotti M, Bottelli C, Conconi A, Gomez H, Lopez-Guillermo A, Martinelli G, Merli F, Novero D, Orsucci L, Pavone V, Ricardi U, Storti S, Gospodarowicz MK, Cavalli F, Sarris AH, Zucca E. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial. *J Clin Oncol.* 2011 Jul 10;29(20):2766-72.
130. Coiffier B, Osmanov EA, Hong X, Scheliga A, Mayer J, Offner F, Rule S, Teixeira A, Walewski J, de Vos S, Crump M, Shpilberg O, Esseltine DL, Zhu E, Enny C, Theoharous P, van de Velde H, Elsayed YA, Zinzani PL; LYM-3001 study investigators. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naïve or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. *Lancet Oncol.* 2011 Aug;12(8):773-84. Epub 2011 Jul 1.
131. Tedeschi A, Benevolo G, Varettoni M, Battista ML, Zinzani PL, Visco C, Meneghini V, Pioltelli P, Sacchi S, Ricci F, Nichelatti M, Zaja F, Lazzarino M, **Vitolo U**, Morra E. Fludarabine plus cyclophosphamide and rituximab in Waldenström macroglobulinemia: An effective but myelosuppressive regimen to be offered to patients with advanced disease. *Cancer.* 2011 Jul 5.

132. Viviani S, Zinzani PL, Rambaldi A, Brusamolino E, Levis A, Bonfante V, **Vitolo U**, Pulsoni A, Liberati AM, Specchia G, Valagussa P, Rossi A, Zaja F, Pogliani EM, Pregno P, Gotti M, Gallamini A, Rota Scalabrini D, Bonadonna G, Gianni AM; Michelangelo Foundation; Gruppo Italiano di Terapie Innovative nei Linfomi; Intergruppo Italiano Linfomi. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. *N Engl J Med*. 2011 Jul 21;365(3):203-12.
133. Dreyling M, Kluin-Nelemans HC, Beà S, Hartmann E, Salaverria I, Hutter G, Perez-Galan P, Roue G, Pott C, Gouill SL, Cortelazzo S, Rule S, Hess G, Zaja F, **Vitolo U**, Szymczyk M, Walewski J, Ribrag V, Unterhalt M, Hermine O, Hoster E. Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 10th annual conference of the European Mantle Cell Lymphoma Network. *Leuk Lymphoma*. 2011 Aug 18. [Epub ahead of print]
134. Chiappella A, **Vitolo U**. Highlights in lymphoma: overview of the 11th International Conference on Malignant Lymphoma. *Expert Rev Hematol*. 2011 Oct; 4(5):491-4.
135. Zinzani PL, Corradini P, Gallamini A, Grossi A, Lazzarino M, Marchetti M, Martelli M, Rossi G, **Vitolo U**. Overview of of Alemtuzumab therapy for the treatment of T-Cell lymphomas. *Leuk Lymphoma*. 2011 Oct 10.
136. Chisesi T, Bellei M, Luminari S, Montanini A, Marcheselli L, Levis A, Gobbi P, **Vitolo U**, Stelitano C, Pavone V, Merli F, Liberati M, Baldini L, Bordonaro R, Pesce EA, Federico M. Long-Term Follow-Up Analysis of HD9601 Trial Comparing ABVD Versus Stanford V Versus MOPP/EBV/CAD in Patients With Newly Diagnosed Advanced-Stage Hodgkin's Lymphoma: A Study From the Intergruppo Italiano Linfomi. *J Clin Oncol*. 2011 Oct 11. [Epub ahead of print]
137. Dreyling M, Ghielmini M, Marcus R, Salles G, **Vitolo U**. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. ESMO Guidelines Working Group. *Ann Oncol*. 2011 Sep;22 Suppl 6
138. Zaja F, De Luca S, Vitolo U, Orsucci L, Levis A, Salvi F, Rusconi C, Ravelli E, Tucci A, Bottelli C, Balzarotti M, Brusamolino E, Bonfichi M, Pileri SA, Sabattini E, Volpetti S, Monagheddu C, Vacca A, Ria R, Fanin R. Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neoangiogenic biomarkers. *Haematologica*. 2011 Nov 4. [Epub ahead of print]
139. Corazzelli G, Frigeri F, Russo F, Frairia C, Arcamone M, Esposito G, De Chiara A, Morelli E, Capobianco G, Becchimanzi C, Volzone F, Saggese M, Marcacci G, De Filippi R, Vitolo U, Pinto A. RD-CODOX-M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and 'unclassifiable' highly aggressive B-cell lymphoma. *Br J Haematol*. 2012 Jan;156(2):234-44.
140. Ferrario A, Pulsoni A, Olivero B, Rossi G, Vitolo U, Tedeschi A, Merli F, Rigacci L, Stelitano C, Goldaniga M, Mannina D, Musto P, Rossi F, Gamba E, Baldini L. Fludarabine, cyclophosphamide, and rituximab in patients with advanced, untreated, indolent B-cell nonfollicular lymphomas: Phase 2 study of the Italian Lymphoma Foundation. *Cancer*. 2011 Dec 16. doi: 10.1002/cncr.26708. [Epub ahead of print]
141. Pregno P, Chiappella A, Bellò M, Botto B, Ferrero S, Franceschetti S, Giunta F, Ladetto M, Limerutti G, Menga M, Nicolosi M, Priolo G, Puccini B, Rigacci L, Salvi F, Vaggelli L, Passera R, Bisi G, Vitolo U. The interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. *Blood*. 2012 Mar 1;119(9):2066-73.
142. Chiappella A, Vitolo U. Lenalidomide in diffuse large B-cell lymphomas. *Adv Hematol*. 2012;2012:498342. doi: 10.1155/2012/498342. Epub 2012 Jun 27.
143. Benevolo G, Stacchini A, Spina M, Ferreri AJ, Arras M, Bellio L, Botto B, Bulian P, Cantonetti M, Depaoli L, Di Renzo N, Di Rocco A, Evangelista A, Franceschetti S, Godio L, Mannelli F, Pavone V, Pioltelli P, Vitolo U, Pogliani EM; Fondazione Italiana Linfomi. Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination. *Blood*. 2012 Oct 18;120(16):3222-8. doi: 10.1182/blood-2012-04-423095. Epub 2012 Aug 27

144. Dreyling M, Kluijn-Nelemans HC, Beà S, Klapper W, Vogt N, Delfau-Larue MH, Hutter G, Cheah C, Chiappella A, Cortelazzo S, Pott C, Hess G, Visco C, Vitolo U, Klener P, Aurer I, Unterhalt M, Ribrag V, Hoster E, Hermine O; for the European MCL Network. Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 11th annual conference of the European Mantle Cell Lymphoma Network. *Leuk Lymphoma*. 2012 Nov 21. [Epub ahead of print]
145. Filippi AR, Botticella A, Bellò M, Botto B, Castiglione A, Gavarotti P, Gottardi D, Parvis G, Bisi G, Levis A, Vitolo U, Ricardi U. Interim positron emission tomography and clinical outcome in patients with early stage Hodgkin lymphoma treated with combined modality therapy. *Leuk Lymphoma*. 2012 Nov 1. [Epub ahead of print]
146. Tilly H, Vitolo U, Walewski J, da Silva MG, Shpilberg O, André M, Pfreundschuh M, Dreyling M; ESMO Guidelines Working Group. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2012 Oct;23 Suppl 7:vii78-82.
147. Ghilmini M, Vitolo U, Kimby E, Montoto S, Walewski J, Pfreundschuh M, Federico M, Hoskin P, McNamara C, Caligaris-Cappio F, Stilgenbauer S, Marcus R, Trneny M, Dreger P, Montserrat E, Dreyling M; On behalf of the Panel Members of the 1st ESMO Consensus Conference on Malignant Lymphoma. ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). *Ann Oncol*. 2012 Nov 21. [Epub ahead of print]
148. Zucca E, Conconi A, Laszlo D, López-Guillermo A, Bouabdallah R, Coiffier B, Sebban C, Jardin F, Vitolo U, Morschhauser F, Pileri SA, Copie-Bergman C, Campo E, Jack A, Floriani I, Johnson P, Martelli M, Cavalli F, Martinelli G, Thieblemont C. Addition of Rituximab to Chlorambucil Produces Superior Event-Free Survival in the Treatment of Patients With Extranodal Marginal-Zone B-Cell Lymphoma: 5-Year Analysis of the IELSG-19 Randomized Study. *J Clin Oncol*. 2013 Feb 10;31(5):565-72. doi: 10.1200/JCO.2011.40.6272. Epub 2013 Jan 7.
149. Zinzani PL, Marchetti M, Billio A, Barosi G, Carella AM, Lazzarino M, Martelli M, Rambaldi A, Rigacci L, Tarella C, Vitolo U, Tura S. SIE, SIES, GITMO revised guidelines for the management of follicular lymphoma. *Am J Hematol*. 2013 Mar;88(3):185-92. doi: 10.1002/ajh.23372. Epub 2013 Jan 22.
150. Riera L, Marmont F, Toppino D, Frairia C, Sismondi F, Audisio E, Di Bello C, D'Ardia S, Di Celle PF, Messa E, Inghirami G, Vitolo U, Pich A. Core binding factor acute myeloid leukaemia and c-KIT mutations. *Oncol Rep*. 2013 May;29(5):1867-72. Epub 2013 Mar 5.
151. Tedeschi A, Ricci F, Goldaniga MC, Benevolo G, Varettoni M, Motta M, Pioltelli P, Gini G, Barate' C, Luraschi A, Vismara E, Frustaci AM, Nichelatti M, Vitolo U, Baldini L, Morra E. Fludarabine, cyclophosphamide, and rituximab in salvage therapy of Waldenström's macroglobulinemia. *Clin Lymphoma Myeloma Leuk*. 2013 Apr;13(2):231-4. Epub 2013 Mar 13.
152. Federico M, Luminari S, Dondi A, Tucci A, Vitolo U, Rigacci L, Di Raimondo F, Carella AM, Pulsoni A, Merli F, Arcaini L, Angrilli F, Stelitano C, Gaidano G, Dell'olio M, Marcheselli L, Franco V, Galimberti S, Sacchi S, Brugiatelli M. R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. *J Clin Oncol*. 2013 Apr 20;31(12):1506-13. Epub 2013 Mar 25.
153. Zinzani PL, Viviani S, Anastasia A, Vitolo U, Luminari S, Zaja F, Corradini P, Spina M, Brusamolino E, Gianni AM, Santoro A, Botto B, Derenzini E, Pellegrini C, Argnani L. Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: Italian experience and results of the use in the daily clinic outside clinical trials. *Haematologica*. 2013 May 3. [Epub ahead of print]
154. Liberati AM, Vitolo U, Palumbo A, Cortelezzi A. Lenalidomide in the treatment of lymphoproliferative disorders and multiple myeloma. *Adv Hematol*. 2013;2013:812605. Epub 2013 Apr 16. No abstract available.
155. Benevolo G, Chiappella A, Vitolo U. XVI. CNS prophylaxis in aggressive lymphomas: for whom and how. *Hematol Oncol*. 2013 Jun;31 Suppl 1:89-91. No abstract available.
156. Busca A, Pecoraro C, Giaccone L, Bruno B, Allione B, Corsetti MT, Pini M, Marmont F, Audisio E, D'Ardia S, Frairia C, Castiglione A, Ciccone G, Levis A, Vitolo U, Falda M. Allogeneic Stem Cell Transplantation

- (Hsct) For Adults With Myelodysplastic Syndromes (Mds): Relevance Of Pre-Transplant Disease Status. *Leuk Lymphoma*. 2013 Jun 19. [Epub ahead of print]
157. Chiappella A, Tucci A, Castellino A, Pavone V, Baldi I, Carella AM, Orsucci L, Zanni M, Salvi F, Liberati AM, Gaidano G, Bottelli C, Rossini B, Perticone S, De Masi P, Ladetto M, Ciccone G, Palumbo A, Rossi G, Vitolo U. Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated elderly diffuse large B-cell lymphoma patients: phase I study by the Fondazione Italiana Linfomi. *Haematologica*. 2013 Jun 28. [Epub ahead of print]
158. Radford J, Davies A, Cartron G, Morschhauser F, Salles G, Marcus R, Wenger M, Lei G, Wassner-Fritsch E, Vitolo U. Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000). *Blood*. 2013 Jul 10. [Epub ahead of print].
159. Zaja F, Federico M, Vitolo U, Zinzani PL. *Leuk Lymphoma*. 2013 Aug 31. [Epub ahead of print]. Management of relapsed/refractory mantle cell lymphoma: a review of current therapeutic strategies.
160. Filippi AR, Piva C, Giunta F, Bellò M, Chiappella A, Caracciolo D, Zotta M, Douroukas A, Ragona R, Vitolo U, Bisi G, Ricardi U. Radiation therapy in primary mediastinal B-cell lymphoma with positron emission tomography positivity after rituximab chemotherapy. *Int J Radiat Oncol Biol Phys*. 2013 Oct 1;87(2):311-6. doi: 10.1016/j.ijrobp.2013.05.053. Epub 2013 Aug 2.
161. Vitolo U, Ladetto M, Boccomini C, Baldini L, De Angelis F, Tucci A, Botto B, Chiappella A, Chiarenza A, Pinto A, De Renzo A, Zaja F, Castellino C, Bari A, Alvarez De Celis I, Evangelista A, Parvis G, Gamba E, Lobetti-Bodoni C, Ciccone G, Rossi G. Rituximab Maintenance Compared With Observation After Brief First-Line R-FND Chemoimmunotherapy With Rituximab Consolidation in Patients Age Older Than 60 Years With Advanced Follicular Lymphoma: A Phase III Randomized Study by the Fondazione Italiana Linfomi. *J Clin Oncol*. 2013 Sep 20;31(27):3351-3359. Epub 2013 Aug 19.
162. Quaglino P, Nardò T, Fierro MT, Massaia M, Orsucci L, Fava P, Marengo F, Marra E, Savoia P, Vitolo U, Boccadoro M, Bernengo M. Clinicopathologic spectrum of cutaneous diseases in patients with hematologic malignancies with or without allogeneic bone marrow transplantation: an observational cohort study in 101 patients. *G Ital Dermatol Venereol*. 2013 Oct;148(5):453-63.
163. Chiappella A, Benevolo G, Vitolo U. Extranodal lymphomas. *Rinsho Ketsueki*. 2013 Oct;54(10):1843-9. No abstract available.
164. Dellacasa CM, Busca A, Audisio E, Marmont F, Barbui AM, Falda M, De Rosa FG, Frairia C, Allione B, D'Ardia S, Aydin S, Pecoraro C, Manetta S, Vitolo U. Prevention of invasive fungal infections in patients with acute myeloid leukaemia: results of a single centre retrospective observational study with the use of posaconazole versus conventional mould-active azoles. *J Chemother*. 2013 Sep 26. [Epub ahead of print] No abstract available.
165. Ladetto M, Lobetti-Bodoni C, Mantoan B, Ceccarelli M, Boccomini C, Genuardi E, Chiappella A, Baldini L, Rossi G, Pulsoni A, Di Raimondo F, Rigacci L, Pinto A, Galimberti S, Bari A, Rota-Scalabrini D, Ferrari A, Zaja F, Gallamini A, Specchia G, Musto P, Rossi FG, Gamba E, Evangelista A, Vitolo U. Persistence of minimal residual disease in the bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program. *Blood*. 2013 Oct 1. [Epub ahead of print]
166. Benevolo G, Chiappella A, Vitolo U. The risk of CNS involvement in aggressive lymphomas in the rituximab era. *Expert Rev Hematol*. 2013 Dec;6(6):643-52. doi: 10.1586/17474086.2013.850896. Epub 2013 Oct 30.
167. Ibatci A, Pica GM, Nati S, Vitolo U, Botto B, Ciochetto C, Petrini M, Galimberti S, Ciabatti E, Orciuolo E, Zinzani PL, Cascavilla N, Guolo F, Fraternali Orcioni G, Carella AM. Safety and efficacy of 90 Yttrium-Ibritumomab-Tiuxetan for untreated follicular lymphoma patients. An Italian cooperative study. *Br J Haematol*. 2013 Dec 17. doi: 10.1111/bjh.12695. [Epub ahead of print]
168. Marignani M, Marzano A, Begini P, Vitolo U, Luminari S, Levis A, Deli I, Gigante E, De Santis E, Delle Fave G, Monarca B, Cox MC. Perception of hepatitis B virus infection reactivation-related issues among specialists managing hematologic malignancies: result of an Italian survey. *Leuk Lymphoma*. 2014 Mar 7. [Epub ahead of print]

169. Schmitz N, Ziepert M, Vitolo U; German High-Grade Non-Hodgkin's Lymphoma Study Group; Fondazione Italiana Linfomi. The role of myeloablation for lymphoma. *N Engl J Med*. 2014 Feb 6;370(6):574-5
170. Zinzani PL, Federico M, Oliva S, Pinto A, Rigacci L, Specchia G, Tucci A, Vitolo U. The more patients you treat, the more you cure: managing cardiotoxicity in the treatment of aggressive non-Hodgkin lymphoma. *Leuk Lymphoma*. 2014 Mar 24. [Epub ahead of print]
171. Filippi AR, Ciammella P, Piva C, Ragona R, Botto B, Gavarotti P, Merli F, Vitolo U, Iotti C, Ricardi U. Involved-Site Image-Guided Intensity Modulated Versus 3D Conformal Radiation Therapy in Early Stage Supradiaphragmatic Hodgkin Lymphoma. *Int J Radiat Oncol Biol Phys*. 2014 Mar 7. [Epub ahead of print]
172. Corradini P, Vitolo U, Rambaldi A, Miceli R, Patriarca F, Gallamini A, Olivieri A, Benedetti F, Todeschini G, Rossi G, Salvi F, Bruno B, Baldini L, Ferreri A, Patti C, Tarella C, Pileri S, Doderio A. Intensified chemoimmunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma. *Leukemia*. 2014 Feb 20. [Epub ahead of print]
173. Conconi A, Raderer M, Franceschetti S, Devizzi L, Ferreri AJ, Magagnoli M, Arcaini L, Zinzani PL, Martinelli G, Vitolo U, Kiesewetter B, Porro E, Stathis A, Gaidano G, Cavalli F, Zucca E. Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group. *Br J Haematol*. 2014 Mar 27. [Epub ahead of print]
174. Martelli M, Ceriani L, Zucca E, Zinzani PL, Ferreri AJ, Vitolo U, Stelitano C, Brusamolino E, Cabras MG, Rigacci L, Balzarotti M, Salvi F, Montoto S, Lopez-Guillermo A, Finolezzi E, Pileri SA, Davies A, Cavalli F, Giovanella L, Johnson PW. [18F]Fluorodeoxyglucose Positron Emission Tomography Predicts Survival After Chemoimmunotherapy for Primary Mediastinal Large B-Cell Lymphoma: Results of the International Extranodal Lymphoma Study Group IELSG-26 Study. *J Clin Oncol*. 2014 Jun 10;32(17):1769-75. Epub 2014 May 5.
175. Vitolo U, Chiappella A, Franceschetti S, Carella AM, Baldi I, Inghirami G, Spina M, Pavone V, Ladetto M, Liberati AM, Molinari AL, Zinzani P, Salvi F, Fattori PP, Zaccaria A, Dreyling M, Botto B, Castellino A, Congiu A, Gaudiano M, Zanni M, Ciccone G, Gaidano G, Rossi G; Fondazione Italiana Linfomi. Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial. *Lancet Oncol*. 2014 Jun;15(7):730-7. Epub 2014 May 13.
176. Rossi G, Skert C, Morello E, Almici C, Arcaini L, Basilico C, Cavalli L, Botto B, Castelli A, Pica G, Ripamonti F, Salvi F, Carella AM, Gaidano G, Levis A, Nosari A, Russo D, Vitolo U. PBSC mobilization in lymphoma patients: analysis of risk factors for collection failure and development of a predictive score based on the kinetics of circulating CD34+ cells and WBC after chemotherapy and G-CSF mobilization. *Hematol Oncol*. 2014 May 29. [Epub ahead of print]
177. Robinson S, Dreger P, Caballero D, Corradini P, Geisler C, Ghielmini M, Le Gouill S, Kimby E, Rule S, Vitolo U, Dreyling M, Hermine O. The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma. *Leukemia*. 2014 Jul 18. doi: 10.1038/leu.2014.223. [Epub ahead of print]
178. Tarella C, Arcaini L, Baldini L, Barosi G, Billio A, Marchetti M, Rambaldi A, Vitolo U, Zinzani PL, Tura S. Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation Guidelines for the Management of Indolent, Nonfollicular B-Cell Lymphoma (Marginal Zone, Lymphoplasmacytic, and Small Lymphocytic Lymphoma). *Clin Lymphoma Myeloma Leuk*. 2014 Jul 15. pii: S2152-2650(14)00262-6. doi: 10.1016/j.clml.2014.07.002. [Epub ahead of print] Review.
179. Dreyling M, Ghielmini M, Marcus R, Salles G, Vitolo U, Ladetto M; ESMO Guidelines Working Group. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2014 Sep;25 Suppl 3:iii76-82. doi: 10.1093/annonc/mdu200. Epub 2014 Aug 13.
180. Zinzani PL, Rigacci L, Cox MC, Devizzi L, Fabbri A, Zaccaria A, Zaja F, Di Rocco A, Rossi G, Storti S, Fattori PP, Argnani L, Tura S, Vitolo U. Lenalidomide monotherapy in heavily pretreated patients with non-Hodgkin lymphoma: an Italian observational multicenter retrospective study in daily clinical practice. *Leuk Lymphoma*. 2014 Nov 19:1-6. [Epub ahead of print]

181. Galimberti S, Luminari S, Ciabatti E, Grassi S, Guerrini F, Dondi A, Marcheselli L, Ladetto M, Piccaluga PP, Gazzola A, Mannu C, Monitillo L, Mantoan B, Del Giudice I, Della Starza I, Cavalli M, Arcaini L, Tucci A, Palumbo GA, Rigacci L, Pulsoni A, Vitolo U, Boccomini C, Vallisa D, Bertoldero G, Gaidano G, Musto P, Petrini M, Federico M. Minimal Residual Disease after Conventional Treatment Significantly Impacts on Progression-Free Survival of Patients with Follicular Lymphoma: The FIL FOLL05 Trial. *Clin Cancer Res*. 2014 Oct 14. [Epub ahead of print]
182. Castagnetti F, Gugliotta G, Baccarani M, Breccia M, Specchia G, Levato L, Abruzzese E, Rossi G, Iurlo A, Martino B, Pregno P, Stagno F, Cuneo A, Bonifacio M, Gobbi M, Russo D, Gozzini A, Tiribelli M, de Vivo A, Alimena G, Cavo M, Martinelli G, Pane F, Saglio G, Rosti G; GIMEMA CML Working Party. Differences among young adults, adults and elderly chronic myeloid leukemia patients. *Ann Oncol*. 2015 Jan;26(1):185-92. doi: 10.1093/annonc/mdu490. Epub 2014 Oct 30.
183. Tedeschi A, Picardi P, Ferrero S, Benevolo G, Casaluci Margiotta G, Varettoni M, Baratè C, Motta M, Gini G, Goldaniga MC, Visco C, Zaja F, Belsito Petrizi V, Ravelli E, Gentile M, Urbano MA, Franceschetti S, Ghione P, Orsucci L, Frustaci AM, Gaidano G, Vitolo U, Morra E. Bendamustine and rituximab combination is safe and effective as salvage regimen in waldenstrom's macroglobulinemia. *Leuk Lymphoma*. 2015 Feb 4:1-19. [Epub ahead of print]
184. Giunta F, Zotta M, Menga M, Balma M, Bellò M, Passera R, Filippi AR, Chiappella A, Ladetto M, Ricardi U, Vitolo U, Bisi G. Using PET-CT in the Restaging of Primitive Mediastinal B-Cell Lymphoma (PMBCL) after chemotherapy: which criterion should we use? *Q J Nucl Med Mol Imaging*. 2015 Feb 11. [Epub ahead of print]
185. Witzig TE, Nowakowski GS, Habermann TM, Goy A, Hernandez-Ilizaliturri FJ, Chiappella A, Vitolo U, Fowler N, Czuczman MS. A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma. *Ann Oncol*. 2015 Aug;26(8):1667-77. doi: 10.1093/annonc/mdv102. Epub 2015 Feb 23. Review
186. Rigacci L, Puccini B, Zinzani PL, Biggi A, Castagnoli A, Merli F, Balzarotti M, Stelitano C, Spina M, Vitolo U, Stefoni V, Levis A, Gotti M, Rosaria S, Maria SP, Bosi A, Gallamini A. The prognostic value of positron emission tomography performed after two courses (INTERIM-PET) of standard therapy on treatment outcome in early stage Hodgkin lymphoma: A multicentric study by the fondazione italiana linfomi (FIL). *Am J Hematol*. 2015 Jun;90(6):499-503. doi: 10.1002/ajh.23994. Epub 2015 May 10.
187. Robak T, Huang H, Jin J, Zhu J, Liu T, Samoiloa O, Pylypenko H, Verhoef G, Siritanaratkul N, Osmanov E, Alexeeva J, Pereira J, Drach J, Mayer J, Hong X, Okamoto R, Pei L, Rooney B, van de Velde H, Cavalli F; LYM-3002 Investigators. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. *N Engl J Med*. 2015 Mar 5;372(10):944-53. doi: 10.1056/NEJMoa1412096.
188. Zinzani PL, Vitolo U, Viviani S, Corradini P, Motta G, Tani M, Cascavilla N, Hohaus S, Merli F, Argnani L, Broccoli A. Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory hodgkin's lymphoma: experience with 27 patients. *Clin Lymphoma Myeloma Leuk*. 2015 Jul;15(7):404-8. doi: 10.1016/j.clml.2015.02.023. Epub 2015 Mar 5.
189. Tilly H, Gomes da Silva M, Vitolo U, Jack A, Meignan M, Lopez-Guillermo A, Walewski J, André M, Johnson PW, Pfreundschuh M, Ladetto M; ESMO Guidelines Committee. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2015 Sep;26 Suppl 5:v116-v125.
190. Drandi D, Kubiczkoa-Besse L, Ferrero S, Dani N, Passera R, Mantoan B, Gambella M, Monitillo L, Saraci E, Ghione P, Genuardi E, Barbero D, Omedè P, Barberio D, Hajek R, Vitolo U, Palumbo A, Cortelazzo S, Boccadoro M, Inghirami G, Ladetto M. Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCR. *J Mol Diagn*. 2015 Aug 26. pii: S1525-1578(15)00147-6. doi: 10.1016/j.jmoldx.2015.05.007. [Epub ahead of print]
191. Musso M, Messina G, Di Renzo N, Di Carlo P, Vitolo U, Scalone R, Marcacci G, Scalzulli PR, Moscato T, Matera R, Crescimanno A, Santarone S, Orciuolo E, Merenda A, Pavone V, Pastore D, Donnarumma D, Carella AM, Ciochetto C, Cascavilla N, Mele A, Lanza F, Di Nicola M, Bonizzoni E, Pinto A. Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine-based high-dose chemotherapy regimen. *Br J Haematol*. 2016 Jan;172(1):111-21.

192. Palandri F, Polverelli N, Breccia M, Nicolino B, Vitolo U, Alimena G, Cavo M, Vianelli N, Benevolo G. Safety and efficacy of ruxolitinib in myelofibrosis patients without splenomegaly. *Br J Haematol*. 2015 Oct 28.
193. Giaccone L, Audisio E, Bruno B, Maffini E, D'Ardia S, Caracciolo D, Ferrando F, Butera S, Brunello L, Frairia C, Aydin S, Nicolino B, Festuccia M, Crisà E, Bruna R, Passera R, Boccadoro M, Vitolo U, Busca A, Falda M, Marmont F. Role of Chemotherapy and Allografting in the Treatment of Acute Lymphoblastic Leukemia. *Clin Lymphoma Myeloma Leuk*. 2016 Feb;16(2):96-103.
194. Zallio F, Tamiazzo S, Monagheddu C, Merli F, Ilariucci F, Stelitano C, Liberati AM, Mannina D, Vitolo U, Angelucci E, Rota Scalabrini D, Vallisa D, Bellei M, Bari A, Ciccone G, Salvi F, Levis A. Reduced intensity VEPEMB regimen compared with standard ABVD in elderly Hodgkin lymphoma patients: results from a randomized trial on behalf of the Fondazione Italiana Linfomi (FIL). *Br J Haematol*. 2016 Mar;172(6):879-88.
195. Balzarotti M, Brusamolino E, Angelucci E, Carella AM, Vitolo U, Russo E, Congiu A, Gotti M, Massidda S, Botto B, Annechini G, Spina M, Re A, Zilioli VR, Merli F, Salvi F, Stelitano C, Bonfichi M, Rodari M, Murru R, Magagnoli M, Anastasia A, Mazza R, Giordano L, Santoro A. B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL). *Leuk Lymphoma*. 2016 Feb 15:1-7.
196. Zinzani PL, Broccoli A, Gioia DM, Castagnoli A, Ciccone G, Evangelista A, Santoro A, Ricardi U, Bonfichi M, Brusamolino E, Rossi G, Anastasia A, Zaja F, Vitolo U, Pavone V, Pulsoni A, Rigacci L, Gaidano G, Stelitano C, Salvi F, Rusconi C, Tani M, Freilone R, Pregno P, Borsatti E, Sacchetti GM, Argnani L, Levis A. Interim Positron Emission Tomography Response-Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study. *J Clin Oncol*. 2016 Apr 20;34(12):1376-85.
197. Ciammella P, Filippi AR, Simontacchi G, Buglione M, Furlan C, Spina M, Tucci A, Rigacci L, Iotti C, Vitolo U, Ricardi U, Merli F. Alternative options for elderly patients with limited stage diffuse large B-cell lymphoma: R-chemotherapy vs. R-chemotherapy plus radiotherapy. *Leuk Lymphoma*. 2016 Nov;57(11):2677-80. doi: 10.3109/10428194.2016.1153088.
198. Pellegrini C, Doderò A, Chiappella A, Monaco F, Degl'Innocenti D, Salvi F, Vitolo U, Argnani L, Corradini P, Zinzani PL; Italian Lymphoma Foundation (Fondazione Italiana Linfomi Onlus, FIL). A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients. *J Hematol Oncol*. 2016 Apr 12;9(1):38.
199. Nowakowski GS, Chiappella A, Witzig TE, Spina M, Gascoyne RD, Zhang L, Flament J, Repici J, Vitolo U. ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma. *Future Oncol*. 2016 Jul;12(13):1553-63. doi: 10.2217/fo-2016-0130.
200. Filippi AR, Piva C, Levis M, Chiappella A, Caracciolo D, Bellò M, Bisi G, Vitolo U, Ricardi U. Prognostic Role of Pre-Radiation Therapy (18)F-Fluorodeoxyglucose Positron Emission Tomography for Primary Mediastinal B-Cell Lymphomas Treated with R-CHOP or R-CHOP-Like Chemotherapy Plus Radiation. *Int J Radiat Oncol Biol Phys*. 2016 Jul 15;95(4):1239-43. doi: 10.1016/j.ijrobp.2016.02.057.
201. Chauvie S, Bergesio F, Fioroni F, Brambilla M, Biggi A, Versari A, Guerra L, Storto G, Musto P, Luminari S, Cabras MG, Balzarotti M, Rigacci L, Martelli M, Vitolo U, Federico M, Gallamini A. The (68)Ge phantom-based FDG-PET site qualification program for clinical trials adopted by FIL (Italian Foundation on Lymphoma). *Phys Med*. 2016 May;32(5):651-6. doi: 10.1016/j.ejmp.2016.04.004.
202. Zinzani PL, Rigacci L, Cox MC, Devizzi L, Fabbri A, Zaja F, Di Rocco A, Rossi G, Storti S, Fattori PP, Argnani L, Vitolo U. The efficacy of lenalidomide combination therapy in heavily pretreated non-Hodgkin lymphoma patients: an Italian observational, multicenter, retrospective study. *Leuk Lymphoma*. 2016 Jun 2:1-4. No abstract available.
203. Vitolo U, Seymour JF, Martelli M, Illerhaus G, Illidge T, Zucca E, Campo E, Ladetto M; ESMO Guidelines Committee. Extranodal diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2016 Sep;27(suppl 5):v91-v102. No abstract available.
204. Dreyling M, Ghielmini M, Rule S, Salles G, Vitolo U, Ladetto M; ESMO Guidelines Committee. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and

follow-up. *Ann Oncol*. 2016 Sep;27(suppl 5):v83-v90. No abstract available.

205. Agostinelli C, Gallamini A, Stracqualursi L, Agati P, Tripodo C, Fuligni F, Sista MT, Fanti S, Biggi A, Vitolo U, Rigacci L, Merli F, Patti C, Romano A, Levis A, Trentin L, Stelitano C, Borra A, Piccaluga PP, Hamilton-Dutoit S, Kamper P, Zaucha JM, Małkowski B, Kulikowski W, Tajer J, Subocz E, Rybka J, Steidl C, Broccoli A, Argnani L, Gascoyne RD, d'Amore F, Zinzani PL, Pileri SA. The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study. *Lancet Haematol*. 2016 Oct;3(10):e467-e479. doi: 10.1016/S2352-3026(16)30108-9.
206. Polverelli N, Breccia M, Benevolo G, Martino B, Tieghi A, Latagliata R, Sabattini E, Riminucci M, Godio L, Catani L, Nicolosi M, Perricone M, Sollazzo D, Colafigli G, Campana A, Merli F, Vitolo U, Alimena G, Martinelli G, Lewis RE, Vianelli N, Cavo M, Palandri F. Risk Factors for Infections In Myelofibrosis: Role of Disease Status and Treatment. A multicenter study of 507 patients. *Am J Hematol*. 2016 Oct 4. doi: 10.1002/ajh.24572.
207. Levis M, Piva C, Filippi AR, Botto B, Gavarotti P, Pregno P, Nicolosi M, Freilone R, Parvis G, Gottardi D, Vitolo U, Ricardi U. Potential Benefit of Involved-Field Radiotherapy for Patients With Relapsed-Refractory Hodgkin's Lymphoma With Incomplete Response Before Autologous Stem Cell Transplantation. *Clin Lymphoma Myeloma Leuk*. 2016 Sep 17. pii: S2152-2650(16)30564-X. doi: 10.1016/j.clml.2016.09.008. PMID: 27727134
208. Vitolo U, Angrilli F, DeCosta L, Wetten S, Federico M. G-CSF use in patients receiving first-line chemotherapy for non-Hodgkin's lymphoma (NHL) and granulocyte-colony stimulating factors (G-CSF) as observed in clinical practice in Italy. *Med Oncol*. 2016 Dec;33(12):139.
209. Chiappella A, Castellino A, Vitolo U. State-of-the-art Therapy for Advanced-stage Diffuse Large B-cell Lymphoma. *Hematol Oncol Clin North Am*. 2016 Dec; 30(6):1147-1162. doi: 10.1016/j.hoc.2016.07.002. Review.
210. Shi Q, Flowers CR, Hiddemann W, Marcus R, Herold M, Hagenbeek A, Kimby E, Hochster H, Vitolo U, Peterson BA, Gyan E, Ghielmini M, Nielsen T, De Bedout S, Fu T, Valente N, Fowler NH, Hoster E, Ladetto M, Morschhauser F, Zucca E, Salles G, Sargent DJ. *J Clin Oncol*. 2016 Dec 28;JCO2016708651. [Epub ahead of print] PMID: 280293
211. Castellino A, Santambrogio E, Nicolosi M, Botto B, Boccomini C, Vitolo U. Follicular Lymphoma: The Management of Elderly Patient. *Mediterr J Hematol Infect Dis*. 2017 Jan 1;9(1):e2017009. doi: 10.4084/MJHID.2017.009. eCollection 2017. Review. PMID: 28105297
212. Visco C, Chiappella A, Nassi L, Patti C, Ferrero S, Barbero D, Evangelista A, Spina M, Molinari A, Rigacci L, Tani M, Rocco AD, Pinotti G, Fabbri A, Zambello R, Finotto S, Gotti M, Carella AM, Salvi F, Pileri SA, Ladetto M, Ciccone G, Gaidano G, Ruggeri M, Martelli M, Vitolo U. Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi. *Lancet Haematol*. 2016 Dec 2. pii: S2352-3026(16)30185-5. doi: 10.1016/S2352-3026(16)30185-5. [Epub ahead of print]
213. Zucca E, Conconi A, Martinelli G, Bouabdallah R, Tucci A, Vitolo U, Martelli M, Pettengell R, Salles G, Sebban C, Guillermo AL, Pinotti G, Devizzi L, Morschhauser F, Tilly H, Torri V, Hohaus S, Ferreri AJ, Zachée P, Bosly A, Haioun C, Stelitano C, Bellei M, Ponzoni M, Copie-Bergman C, Jack A, Campo E, Mazzucchelli L, Cavalli F, Johnson P, Thieblemont C. Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy. *J Clin Oncol*. 2017 Mar 29; JCO 2016706994. doi:10.1200/JCO.2016.70.6994. [Epub ahead of print]
214. Nowakowski GS, Vitolo U. Recent advances in clinical studies and the evolving role of subtyping for patients with diffuse large B-cell lymphoma. *Future Oncol*. 2017 Apr;13(10):859-862. doi: 10.2217/fon-2016-0567. Epub 2017 Feb 10. No abstract available. PMID:28183193
215. Chiappella A, Castellino A, Nicolosi M, Santambrogio E, Vitolo U. Diffuse Large B-cell Lymphoma in the elderly: standard treatment and new perspectives. *Expert Rev Hematol*. 2017 Apr;10(4):289-297. doi: 10.1080/17474086.2017.1305264. Epub 2017 Mar 27. PMID: 28290728

216. Santi RM, Ceccarelli M, Catania G, Monagheddu C, Evangelista A, Bernocco E, Monaco F, Federico M, Vitolo U, Cortelazzo S, Cabras MG, Spina M, Baldini L, Boccomini C, Chiappella A, Bari A, Luminari S, Calabrese M, Levis A, Visco C, Contino L, Ciccone G, Ladetto M. PO-03 - Khorana score and histotype predict the incidence of early venous thromboembolism (VTE) in Non Hodgkin Lymphoma (NHL). A pooled data analysis of twelve clinical trials of Fondazione Italiana Linfomi (FIL). *Thromb Haemost.* 2017 Apr 27. doi: 10.1160/TH16-11-0895. [Epub ahead of print] PMID: 28447710
217. Vidal L, Gafter-Gvili A, Salles G, Bousseta S, Oberman B, Rubin C, van Oers MH, Fortpied C, Ghielmini M, Pettengell R, Witzens-Harig M, Dreger P, Vitolo U, Gomes da Silva M, Evangelista A, Li H, Freedman L, Habermann TM, Shpilberg O. Rituximab maintenance improves overall survival of patients with follicular lymphoma-Individual patient data meta-analysis. *Eur J Cancer.* 2017 May;76:216-225. doi: 10.1016/j.ejca.2017.01.021. Epub 2017 Mar 21. PMID: 28336303
218. Dreyling M, Morschhauser F, Bouabdallah K, Bron D, Cunningham D, Assouline SE, Verhoef G, Linton K, Thieblemont C, Vitolo U, Hiemeyer F, Giurescu M, Garcia-Vargas J, Gorbachevsky I, Liu L, Koechert K, Peña C, Neves M, Childs BH, Zinzani PL. Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. *Ann Oncol.* 2017 Jun 14. doi: 10.1093/annonc/mdx289. [Epub ahead of print]
219. Palandri F, Palumbo GA, Bonifacio M, Tiribelli M, Benevolo G, Martino B, Abruzzese E, D'Adda M, Polverelli N, Bergamaschi M, Tieghi A, Cavazzini F, Ibatci A, Crugnola M, Bosi C, Latagliata R, Di Veroli A, Scaffidi L, de Marchi F, Cerqui E, Anaclerico B, De Matteis G, Spinsanti M, Sabattini E, Catani L, Aversa F, Di Raimondo F, Vitolo U, Lemoli RM, Fanin R, Merli F, Russo D, Cuneo A, Bacchi Reggiani ML, Cavo M, Vianelli N, Breccia M. Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis. *Oncotarget.* 2017 Jun 27. doi: 10.18632/oncotarget.18674. [Epub ahead of print] Review.
220. Benevolo G, Nicolosi M, Santambrogio E, Vitolo U. Current options to manage Waldenström's macroglobulinemia. *Expert Rev Hematol.* 2017 Jul;10(7):637-647. doi: 10.1080/17474086.2017.1339596. Epub 2017 Jun 19.
221. Cascione L, Rinaldi A, Chiappella A, Kwee I, Ciccone G, Altenbuchinger M, Kohler C, Vitolo U, Inghirami G, Bertoni F. Diffuse large B cell lymphoma cell of origin by digital expression profiling in the REAL07 Phase 1-2 study. *Br J Haematol.* 2017 Jul 24. doi: 10.1111/bjh.14817. [Epub ahead of print]
222. Chiappella A, Martelli M, Angelucci E, Brusamolino E, Evangelista A, Carella AM, Stelitano C, Rossi G, Balzarotti M, Merli F, Gaidano G, Pavone V, Rigacci L, Zaja F, D'Arco A, Cascavilla N, Russo E, Castellino A, Gotti M, Congiu AG, Cabras MG, Tucci A, Agostinelli C, Ciccone G, Pileri SA, Vitolo U. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. *Lancet Oncol.* 2017 Aug;18(8):1076-1088. doi: 10.1016/S1470-2045(17)30444-8. Epub 2017 Jun 28.
223. Chiappella A, Santambrogio E, Castellino A, Nicolosi M, Vitolo U. Integrating novel drugs to chemoimmunotherapy in diffuse large B-cell lymphoma. *Expert Rev Hematol.* 2017 Aug;10(8):697-705. doi: 10.1080/17474086.2017.1350164. Epub 2017 Jul 14.
224. Giaccone L, Festuccia M, Zallio F, Sorasio R, Brunello L, Maffini E, Dellacasa C, Passera R, Iovino G, Aydin S, Boccadoro M, Vitolo U, Mordini N, Pini M, Busca A, Bruno B. Long-term follow-up of allogeneic stem cell transplantation in relapsed/refractory Hodgkin lymphoma *Bone Marrow Transplant.* 2017 Aug;52(8):1208-1211. doi: 10.1038/bmt.2017.99. Epub 2017 Jun 5.
225. Vitolo U, Trněný M, Belada D, Burke JM, Carella AM, Chua N, Abrisqueta P, Demeter J, Flinn I, Hong X, Kim WS, Pinto A, Shi YK, Tatsumi Y, Oestergaard MZ, Wenger M, Fingerle-Rowson G, Catalani O, Nielsen T, Martelli M, Sehn LH. J Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma. *Clin Oncol.* 2017 Aug 10;JCO2017733402. doi: 10.1200/JCO.2017.73.3402. [Epub ahead of print]
226. Frairia C, Aydin S, Audisio E, Riera L, Aliberti S, Allione B, Busca A, D'Archia S, Dellacasa CM, Demurtas A, Evangelista A, Ciccone G, Francia di Celle P, Nicolino B, Stacchini A, Marmont F, Vitolo U. Post-

- remissional and pre-transplant role of minimal residual disease detected by WT1 in acute myeloid leukemia: A retrospective cohort study. *Leuk Res.* 2017 Oct;61:10-17. doi: 10.1016/j.leukres.2017.08.008. Epub 2017 Aug 30.
227. Chiappella A, Martelli M, Evangelista A, Vitolo U. Chiappella A, Martelli M, Evangelista A, Vitolo U. Rituximab and autologous stem-cell transplantation for high-risk diffuse large B-cell lymphoma - Authors' reply. *Lancet Oncol.* 2017 Oct;18(10):e558. doi: 10.1016/S1470-2045(17)30702-7. No abstract available.
228. Luminari S, Ferrari A, Manni M, Dondi A, Chiarenza A, Merli F, Rusconi C, Tarantino V, Tucci A, Vitolo U, Kovalchuk S, Angelucci E, Pulsoni A, Arcaini L, Angrilli F, Gaidano G, Stelitano C, Bertoldero G, Cascavilla N, Salvi F, Ferreri AJM, Vallisa D, Marcheselli L, Federico M. J. Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma. *Clin Oncol.* 2018 Mar 1;36(7):689-696. doi: 10.1200/JCO.2017.74.1652. Epub 2017 Nov 2.
229. Palandri F, Palumbo GA, Bonifacio M, Tiribelli M, Benevolo G, Martino B, Abruzzese E, D'Adda M, Polverelli N, Bergamaschi M, Tieghi A, Cavazzini F, Ibatici A, Crugnola M, Bosi C, Latagliata R, Di Veroli A, Scaffidi L, de Marchi F, Cerqui E, Anaclerico B, De Matteis G, Spinsanti M, Sabbatini E, Catani L, Aversa F, Di Raimondo F, Vitolo U, Lemoli RM, Fanin R, Merli F, Russo D, Cuneo A, Bacchi Reggiani ML, Cavo M, Vianelli N, Breccia M. Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis. *Oncotarget.* 2017 Jun 27;8(45):79073-79086. doi: 10.18632/oncotarget.18674. eCollection 2017 Oct 3.
230. Ghione P, Cavallo F, Visco C, Chen Z, Castellino A, Tisi MC, Dogliotti I, Nicolosi M, Boccadoro M, Leonard JP, Vitolo U, Martin P. A retrospective study of R-DHAP/Ox for early progressing follicular lymphoma. *Br J Haematol.* 2018 Dec;183(5):828-831. doi: 10.1111/bjh.15057. Epub 2017 Dec 19. No abstract available
231. Vitolo U, Chiappella A. Salvage regimens for Hodgkin's lymphoma in the brentuximab vedotin era. *Lancet Oncol.* 2018 Feb;19(2):162-163. doi: 10.1016/S1470-2045(17)30913-0. Epub 2017 Dec 21. No abstract available.
232. Bomben R, Ferrero S, D'Agaro T, Dal Bo M, Re A, Evangelista A, Carella AM, Zamò A, Vitolo U, Omedè P, Rusconi C, Arcaini L, Rigacci L, Luminari S, Piccin A, Liu D, Wiestner A, Gaidano G, Cortelazzo S, Ladetto M, Gattei V. A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trial. *Haematologica.* 2018 May;103(5):849-856. doi: 10.3324/haematol.2017.184325. Epub 2018 Feb 22
233. Boriani G, Corradini P, Cuneo A, Falanga A, Foà R, Gaidano G, Ghia PP, Martelli M, Marasca R, Massaia M, Mauro FR, Minotti G, Molica S, Montillo M, Pinto A, Tedeschi A, Vitolo U, Zinzani PL. Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding. *Hematol Oncol.* 2018 Oct;36(4):624-632. doi: 10.1002/hon.2503. Epub 2018 Mar 7. Review.
234. Zaja F, Salvi F, Rossi M, Sabbatini E, Evangelista A, Ciccone G, Angelucci E, Gaidano G, Zanni M, Ladetto M, Chiappella A, Vitolo U, Zinzani PL, Califano C, Tucci A, Patti C, Pileri SA, Lenti V, Piccaluga PP, Cavallo F, Volpetti S, Perali G, Assouline S, Mann KK, Morin R, Alcaide M, Bushell K, Fanin R, Levis A. Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi. *Leuk Lymphoma.* 2018 Apr 4:1-7. doi:10.1080/10428194.2018.1452208. [Epub ahead of print]
235. Polverelli N, Palumbo GA, Binotto G, Abruzzese E, Benevolo G, Bergamaschi M, Tieghi A, Bonifacio M, Breccia M, Catani L, Tiribelli M, D'Adda M, Sgherza N, Isidori A, Cavazzini F, Martino B, Latagliata R, Crugnola M, Heidel F, Bosi C, Ibatici A, Soci F, Penna D, Scaffidi L, Aversa F, Lemoli RM, Vitolo U, Cuneo A, Russo D, Cavo M, Vianelli N, Palandri F. Epidemiology, outcome, and risk factors for infectious

- complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients. *Hematol Oncol.* 2018 Apr 6. doi: 10.1002/hon.2509. [Epub ahead of print]
236. Ciochetto C, Botto B, Passera R, Bellò M, Benevolo G, Boccomini C, Castellino A, Chiappella A, Freilone R, Nicolosi M, Orsucci L, Pecoraro C, Pregno P, Bisi G, Vitolo U. ttrium-90 Yibritumomab tiuxetan (Zevalin) followed by BEAM (Z-BEAM) conditioning regimen and autologous stem cell transplantation (ASCT) in relapsed or refractory high-risk B-cell non-Hodgkin lymphoma (NHL): a single institution Italian experience. *Ann Hematol.* 2018 Sep;97(9):1619-1626. doi: 10.1007/s00277-018-3328-3. Epub 2018 Apr 16.
237. Carella AM, Corradini P, Mussetti A, Ricardi U, Vitolo U, Viviani S. Treatment of classical Hodgkin lymphoma in the era of brentuximab vedotin and immune checkpoint inhibitors. *Ann Hematol.* 2018 Aug;97(8):1301-1315. doi: 10.1007/s00277-018-3366-x. Epub 2018 May 25. Review.
238. Gopal AK, Schuster SJ, Fowler NH, Trotman J, Hess G, Hou JZ, Yacoub A, Lill M, Martin P, Vitolo U, Spencer A, Radford J, Jurczak W, Morton J, Caballero D, Deshpande S, Gartenberg GJ, Wang SS, Damle RN, Schaffer M, Balasubramanian S, Vermeulen J, Cheson BD, Salles G. Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study. *J Clin Oncol.* 2018 Aug 10;36(23):2405-2412. doi: 10.1200/JCO.2017.76.8853. Epub 2018 May 31.
239. Derenzini E, Agostinelli C, Rossi A, Rossi M, Scellato F, Melle F, Motta G, Fabbri M, Diop F, Kodipad AA, Chiappella A, Vitolo U, Gaidano G, Tarella C, Pileri S. Genomic alterations of ribosomal protein genes in diffuse large B cell lymphoma. *Br J Haematol.* 2018 Jun 17. doi: 10.1111/bjh.15442. [Epub ahead of print] No abstract available.
240. Ayed AO, Chiappella A, Pederson L, Laplant BR, Congiu AG, Gaidano G, Spina M, Re A, Cavallo F, Musuraca G, Macon WR, Witzig T, Vitolo U, Nowakowski GS. CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies. *Blood Cancer J.* 2018 Jun 26;8(7):63. doi: 10.1038/s41408-018-0097-0.
241. Palandri F, Catani L, Bonifacio M, Benevolo G, Heidel F, Palumbo GA, Crugnola M, Abruzzese E, Bartoletti D, Polverelli N, Bergamaschi M, Tiribelli M, Iurlo A, Breccia M, Cavazzini F, Tieghi A, Binotto G, Isidori A, Martino B, D'Adda M, Bosi C, Sabattini E, Vitolo U, Aversa F, Ibatici A, Lemoli RM, Sgherza N, Cuneo A, Martinelli G, Semenzato G, Cavo M, Vianelli N, Sapienza MR, Latagliata R. Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients. *Br J Haematol.* 2018 Oct;183(1):35-46. doi: 10.1111/bjh.15497. Epub 2018 Jul 16.
242. Vitolo U, Chiappella A. Brentuximab vedotin-based salvage treatment in Hodgkin's lymphoma. *Lancet Oncol.* 2018 Sep;19(9):1144-1146. doi: 10.1016/S1470-2045(18)30510-2. Epub 2018 Aug 16. No abstract available.
243. Ciavarella S, Vegliante MC, Fabbri M, De Summa S, Melle F, Motta G, De Iuliis V, Opinto G, Enjuanes A, Rega S, Gulino A, Agostinelli C, Scattone A, Tommasi S, Mangia A, Mele F, Simone G, Zito AF, Ingravallo G, Vitolo U, Chiappella A, Tarella C, Gianni AM, Rambaldi A, Zinzani PL, Casadei B, Derenzini E, Loseto G, Pileri A, Tabanelli V, Fiori S, Rivas-Delgado A, López-Guillermo A, Venesio T, Sapino A, Campo E, Tripodo C, Guarini A, Pileri SA. Dissection of DLBCL Microenvironment Provides a Gene Expression-Based Predictor of Survival Applicable to Formalin-Fixed Paraffin-Embedded Tissue. *Ann Oncol.* 2018 Oct 11. doi: 10.1093/annonc/mdy450. [Epub ahead of print]
244. Robak T, Jin J, Pylypenko H, Verhoef G, Siritanaratkul N, Drach J, Raderer M, Mayer J, Pereira J, Tumyan G, Okamoto R, Nakahara S, Hu P, Appiani C, Nemat S, Cavalli F; LYM-3002 investigators. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible

- patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study. *Lancet Oncol.* 2018 Oct 18. pii: S1470-2045(18)30685-5. doi: 10.1016/S1470-2045(18)30685-5. [Epub ahead of print]
245. Vitolo U, Chiappella A. Histological transformation and secondary malignancies in follicular lymphoma. *Lancet Haematol.* 2018 Nov;5(11):e496-e497. doi: 10.1016/S2352-3026(18)30170-4. No abstract available.
246. Visco C, Tisi MC, Evangelista A, Di Rocco A, Zoellner AK, Zilioli VR, Hohaus S, Sciarra R, Re A, Tecchio C, Chiappella A, Morello L, Gini G, Nassi L, Perrone T, Molinari AL, Fabbri A, Cox MC, Finolezzi E, Ferrero S, Puccini B, Alvarez De Celis I, Arcari A, Marino D, Merli M, Piazza F, Gentile M, Pelosini M, Loseto G, Hermine O, Dreyling M, Ruggeri M, Martelli M, Hoster E, Vitolo U; Fondazione Italiana Linfomi and the Mantle Cell Lymphoma Network. Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death. *Br J Haematol.* 2018 Nov 8. doi: 10.1111/bjh.15643. [Epub ahead of print] No abstract available.
247. Castellino A, Chiappella A, LaPlant BR, Pederson LD, Gaidano G, Macon WR, Inghirami G, Reeder CB, Tucci A, King RL, Congiu A, Foran JM, Pavone V, Rivera CE, Spina M, Ansell SM, Cavallo F, Molinari AL, Ciccone G, Habermann TM, Witzig TE, Vitolo U, Nowakowski GS. Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials. *Blood Cancer J.* 2018 Nov 8;8(11):108. doi: 10.1038/s41408-018-0145-9.
248. Horwitz S, O'Connor OA, Pro B, Illidge T, Fanale M, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G, Kim WS, Feldman T, Lennard A, Belada D, Illés Á, Tobinai K, Tsukasaki K, Yeh SP, Shustov A, Hüttmann A, Savage KJ, Yuen S, Iyer S, Zinzani PL, Hua Z, Little M, Rao S, Woolery J, Manley T, Trümper L; ECHELON-2 Study Group. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. *Lancet.* 2019 Jan 19;393(10168):229-240. doi: 10.1016/S0140-6736(18)32984-2. Epub 2018 Dec 4
249. Klanova M, Sehn LH, Bence-Bruckler I, Cavallo F, Jin J, Martelli M, Stewart D, **Vitolo U**, Zaja F, Zhang Q, Mattiello F, Sellam G, Punnoose EA, Szafer-Glusman E, Bolen CR, Oestergaard MZ, Fingerle-Rowson GR, Nielsen T, Trnėny M. Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL. *Blood.* 2019 Feb 28;133(9):919-926. doi: 10.1182/blood-2018-07-862862. Epub 2019 Jan 7. PMID: 30617197
250. Chiappella A, **Vitolo U**. Monoclonal antibody-drug conjugates in B-cell lymphomas. *Lancet Haematol.* 2019 Mar 29. pii: S2352-3026(19)30048-1. doi: 10.1016/S2352-3026(19)30048-1. [Epub ahead of print] No abstract available. PMID: 30935954
251. Klanova M, Oestergaard MZ, Trnėny M, Hiddemann W, Marcus R, Sehn LH, **Vitolo U**, Bazeos A, Goede V, Zeuner H, Knapp A, Sahin D, Spielewoy N, Bolen CR, Cardona A, Klein C, Venstrom JM, Nielsen T, Fingerle-Rowson G. Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy. *Clin Cancer Res.* 2019 May 3. doi: 10.1158/1078-0432.CCR-18-3270. [Epub ahead of print]
252. Novo M, Castellino A, Nicolosi M, Santambrogio E, Vassallo F, Chiappella A, **Vitolo U**. High-grade B-cell lymphoma: how to diagnose and treat. *Expert Rev Hematol.* 2019 Jul;12(7):497-506. doi: 10.1080/17474086.2019.1624157. Epub 2019 Jun 19.
253. Nowakowski GS, Chiappella A, Witzig TE, Scott DW, Spina M, Gascoyne RD, Zhang L, Russo J, Kang J, Zhang J, Xu Y, **Vitolo U**. Variable global distribution of cell-of-origin from the ROBUST phase 3 study in diffuse large B-cell lymphoma. *Haematologica.* 2019 Jun 20. pii: haematol.2019.220475. doi: 10.3324/haematol.2019.220475. [Epub ahead of print]
254. Santambrogio E, Nicolosi M, Vassallo F, Castellino A, Novo M, Chiappella A, **Vitolo U**. Aggressive Non-Hodgkin Lymphomas: risk factors and treatment of central nervous system recurrence. *Expert Rev Hematol.* 2019 Jul 15. doi: 10.1080/17474086.2019.1643232. [Epub ahead of print]

255. Ciavarella S, Vegliante MC, Fabbri M, De Summa S, Melle F, Motta G, De Iuliis V, Opinto G, Enjuanes A, Rega S, Gulino A, Agostinelli C, Scattone A, Tommasi S, Mangia A, Mele F, Simone G, Zito AF, Ingravallo G, **Vitolo U**, Chiappella A, Tarella C, Gianni AM, Rambaldi A, Zinzani PL, Casadei B, Derenzini E, Loseto G, Pileri A, Tabanelli V, Fiori S, Rivas-Delgado A, López-Guillermo A, Venesio T, Sapino A, Campo E, Tripodo C, Guarini A, Pileri SA. Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue. *Ann Oncol*. 2019 Dec 1;30(12):2015. doi: 10.1093/annonc/mdz386.
256. Novo M, Nowakowski GS, Habermann TM, Witzig TE, Micallef IN, Johnston PB, Inwards DJ, Botto B, Ristow KM, Young JR, **Vitolo U**, Ansell SM. Persistent mediastinal FDG uptake on PET-CT after frontline therapy for Hodgkin lymphoma: biopsy, treat or observe? *Leuk Lymphoma*. 2019 Sep 26:1-10. doi:10.1080/10428194.2019.1663422. [Epub ahead of print]
257. Bolen CR, Klanova M, Trnėny M, Sehn LH, He J, Tong J, Paulson JN, Kim E, **Vitolo U**, Di Rocco A, Fingerle-Rowson G, Nielsen T, Lenz G, Oestergaard MZ. Prognostic impact of somatic mutations in diffuse large B-cell lymphoma and relationship to cell-of-origin: data from the phase III GOYA study. *Haematologica*. 2019 Nov 14. pii: haematol.2019.227892. doi: 10.3324/haematol.2019.227892. [Epub ahead of print]
258. Broccoli A, Argnani L, Botto B, Corradini P, Pinto A, Re A, **Vitolo U**, Fanti S, Stefoni V, Zinzani PL; Fondazione Italiana Linfomi ONLUS. First salvage treatment with bendamustine and brentuximab vedotin in Hodgkin lymphoma: a phase 2 study of the Fondazione Italiana Linfomi. *Blood Cancer J*. 2019 Dec 11;9(12):100. doi: 10.1038/s41408-019-0265-x.
259. Bari A, Marcheselli R, Sacchi S, Re A, Pagani C, Tucci A, Botto B, **Vitolo U**, Molinari AL, Puccini B, Pulsoni A, Santoro A, Tani M, Nassi L, Meli E, Pavone V, Bonfichi M, Evangelista A, Gioia D, Levis A, Zinzani P; Fondazione Italiana Linfomi (Onlus). The classic prognostic factors in advanced Hodgkin's lymphoma patients are losing their meaning at the time of Pet-guided treatments. *Ann Hematol*. 2019 Dec 23. doi: 10.1007/s00277-019-03893-7. [Epub ahead of print]
260. Nowakowski GS, Chiappella A, Witzig TE, Scott DW, Spina M, Gascoyne RD, Zhang L, Russo J, Kang J, Zhang J, Xu Y, **Vitolo U**. Variable Global Distribution of Cell-Of-Origin From the ROBUST Phase III Study in Diffuse Large B-cell Lymphoma. *Haematologica*. 2020 Jan 31;105(2):e72-e75. doi: 10.3324/haematol.2019.220475.
261. Baron F, Efficace F, Cannella L, Muus P, Trisolini S, Halkes CJM, Fazi P, Vignetti M, Marie JP, Chiusolo P, van der Velden W, La Sala E, **Vitolo U**, Thomas X, Lefrère F, Di Raimondo F, Bourhis JH, Specchia G, Guimarães JE, Allione B, Vrhovac R, Ferrara F, Stevens-Kroef M, Meert L, de Witte T, Willemze R, Amadori S, Suci S. Impact of the Type of Anthracycline and of Stem Cell Transplantation in Younger Patients With Acute Myeloid Leukaemia: Long-term Follow Up of a Phase III Study. *Am J Hematol*. 2020 Jul;95(7):749-758. doi: 10.1002/ajh.25795. Epub 2020 Apr 17. *Am J Hematol*. 2020 Jul;95(7):749-758. doi: 10.1002/ajh.25795. Epub 2020 Apr 17.
262. Rutherford SC, Herold M, Hiddemann W, Kostakoglu L, Marcus R, Martelli M, Sehn LH, Trnėný M, Trotman J, **Vitolo U**, Nielsen T, Mattiello F, Sahin D, Sellam G, Martin P. Impact of Bone Marrow Biopsy on Response Assessment in Immunochemotherapy-Treated Lymphoma Patients in GALLIUM and GOYA. *Blood Adv*. 2020 Apr 28;4(8):1589-1593.
263. Sehn LH, Martelli M, Trnėný M, Liu W, Bolen CR, Knapp A, Sahin D, Sellam G, **Vitolo U**. A Randomized, Open-Label, Phase III Study of Obinutuzumab or Rituximab Plus CHOP in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma: Final Analysis of GOYA. *J Hematol Oncol*. 2020 Jun 6;13(1):71. doi: 10.1186/s13045-020-00900-7.
264. Rigacci L, Annibali O, Kovalchuk S, Bonifacio E, Pregnotato F, Angrilli F, **Vitolo U**, Pozzi S, Broggi S, Luminari S, Merli F, Spina M, Bolis S, Margiotta-Casaluci G, Scalzulli R, Cox C, Mamusa AM, Santoro A, Zinzani PL, Ferrari S, Gini G, Vigliotti ML, Mulè A, Flenghi L; Fondazione Italiana Linfomi (FIL).

- Nonpegylated Liposomal Doxorubicin Combination Regimen (R-COMP) for the Treatment of Lymphoma Patients With Advanced Age or Cardiac Comorbidity. *Hematol Oncol.* 2020 Jun 16. doi: 10.1002/hon.2764.
265. Santambrogio E, Novo M, Rota-Scalabrini D, **Vitolo U**. Chemotherapy combinations for B-cell lymphoma and chemo-free approach in elderly patients: an update on best practice *Expert Rev Hematol.* 2020 Aug 1:1-19.
266. Michot JM, Bouabdallah R, **Vitolo U**, Doorduijn JK, Salles G, Chiappella A, Zinzani PL, Bijou F, Kersten MJ, Sarmiento R, Mosulen S, Mendez C, Uttamsingh S, Pourdehnad M, Hege K, Chen T, Klein C, Hagner PR, Nikolova Z, Ribrag V. Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study. *Lancet Haematol.* 2020 Sep;7(9):e649-e659
267. Visco C, Di Rocco A, Evangelista A, Quaglia FM, Tisi MC, Morello L, Zilioli VR, Rusconi C, Hohaus S, Sciarra R, Re A, Tecchio C, Chiappella A, Marin-Niebla A, McCulloch R, Gini G, Perrone T, Nassi L, Pennese E, Stefani PM, Cox MC, Bozzoli V, Fabbri A, Polli V, Ferrero S, Celis MIA, Sica A, Petrucci L, Arcaini L, Rule S, Krampera M, **Vitolo U**, Balzarotti M. Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study *Leukemia.* 2020 Aug 11. doi: 10.1038/s41375-020-01013-3
268. Derenzini E, Mazzara S, Melle F, Motta G, Fabbri M, Bruna R, Agostinelli C, Cesano A, Corsini CA, Chen N, Righi S, Sabattini E, Chiappella A, Calleri A, Fiori S, Tabanelli V, Cabras A, Pruneri G, **Vitolo U**, Gianni AM, Rambaldi A, Corradini P, Zinzani PL, Tarella C, Pileri S. A 3-gene signature based on MYC, BCL-2 and NFKBIA improves risk stratification in diffuse large B-cell lymphoma *Haematologica.* 2020 Aug 13:haematol.2019.236455.
269. Vitolo U, Novo M, Santambrogio E. Partial response or better at 6 months is prognostic of superior progression-free survival in patients with Waldenström macroglobulinaemia treated with ibrutinib. *Br J Haematol.* 2020 Nov 18. doi: 10.1111/bjh.17228. Online ahead of print.
270. Punnoose E, Peale FV, Szafer-Glusman E, Lei G, Bourgon R, Do AD, Kim E, Zhang L, Farinha P, Gascoyne RD, Munoz FJ, Martelli M, Mottok A, Salles GA, Sehn LH, Seymour JF, Trněný M, Oestergaard MZ, Mundt KE, Vitolo U. BCL2 Expression in First-Line Diffuse Large B-Cell Lymphoma Identifies a Patient Population With Poor Prognosis. *Clin Lymphoma Myeloma Leuk.* 2020 Nov 10:S2152-2650(20)30628-5. doi:10.1016/j.clml.2020.11.004. Online ahead of print.
271. Szafer-Glusman E, Liu J, Sinha A, Peale FV Jr, Ray J, Horn C, Oestergaard MZ, Kornacker M, Sehn LH, Vitolo U, Knapp A, Venstrom J, Byrtek M, Punnoose E. Evaluation of the effect of prospective biomarker testing on progression-free survival in diffuse large B-cell lymphoma. *Leuk Lymphoma.* 2020 Dec 16:1-4. doi: 10.1080/10428194.2020.1849674. Online ahead of print.
272. Ladetto M, Cortelazzo S, Ferrero S, Evangelista A, Mian M, Tavarozzi R, Zanni M, Cavallo F, Di Rocco A, Stefani V, Pagani C, Re A, Chiappella A, Balzarotti M, Zilioli VR, Gomes da Silva M, Arcaini L, Molinari AL, Ballerini F, Ferreri AJM, Puccini B, Benedetti F, Stefani PM, Narni F, Casaroli I, Stelitano C, Ciccone G, Vitolo U, Martelli M. Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial. *Lancet Haematol.* 2021 Jan;8(1):e34-e44. doi: 10.1016/S2352-3026(20)30358-6. Epub 2020 Dec 22.
273. Boccomini C, Ladetto M, Rigacci L, Puccini B, Rattotti S, Volpetti S, Ferrero S, Chiarenza A, Freilone R, Novo M, Corradini P, Nassi L, Rusconi C, Stelitano C, Bolis S, Marina Liberati A, Tucci A, Baldini L, Balzarotti M, Evangelista A, Ciccone G, Vitolo U. A brief rituximab, bendamustine, mitoxantrone (R-BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL). *Br J Haematol.* 2021 Apr;193(2):280-289. doi: 10.1111/bjh.17283. Epub 2021 Jan 21.

274. Vitolo U, Novo M. Bcl-2 inhibition in DLBCL: "the times they are a-changing"? *Blood*. 2021 Feb 4;137(5):577-579.
275. Nowakowski GS, Chiappella A, Gascoyne RD, Scott DW, Zhang Q, Jurczak W, Özcan M, Hong X, Zhu J, Jin J, Belada D, Bergua JM, Piazza F, Mócikova H, Molinari AL, Yoon DH, Cavallo F, Tani M, Yamamoto K, Izutsu K, Kato K, Czuczman M, Hersey S, Kilcoyne A, Russo J, Hudak K, Zhang J, Wade S, Witzig TE, Vitolo U. ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma. *J Clin Oncol*. 2021 Apr 20;39(12):1317-1328.
276. Kostakoglu L, Martelli M, Sehn LH, Belada D, Carella AM, Chua N, Gonzalez-Barca E, Hong X, Pinto A, Shi Y, Tatsumi Y, Knapp A, Mattiello F, Nielsen T, Sahin D, Sellam G, Oestergaard MZ, Vitolo U, Trněný M. End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA. *Blood Adv*. 2021 Mar 9;5(5):1283-1290.
277. Genuardi E, Klous P, Mantoan B, Drandi D, Ferrante M, Cavallo F, Alessandria B, Dogliotti I, Grimaldi D, Ragaini S, Clerico M, Lo Schirico M, Saraci E, Yilmaz M, Zaccaria GM, Cortelazzo S, Vitolo U, Luminari S, Federico M, Boccadoro M, van Min M, Splinter E, Ladetto M, Ferrero S. Targeted locus amplification to detect molecular markers in mantle cell and follicular lymphoma. *Hematol Oncol*. 2021 Mar 20. doi: 10.1002/hon.2864. Online ahead of print.
278. Casulo C, Dixon JG, Ou FS, Hoster E, Peterson BA, Hochster HS, Brice P, Ladetto M, Hiddemann W, Marcus R, Kimby E, Herold M, Nielsen T, Morschhauser F, Rummel M, Hagenbeek A, Vitolo U, Salles GA, Shi Q, Flowers CR. Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials. *Blood Adv*. 2021 Mar 23;5(6):1737-1745.
279. Novo M, Santambrogio E, Frascione PMM, Rota-Scalabrini D, Vitolo U. Antibody Therapies for Large B-Cell Lymphoma. *Biologics*. 2021 May 18;15:153-174. doi: 10.2147/BTT.S281618.
280. Cortelazzo S, Mian M, Evangelista A, Devizzi L, Corradini P, Magni M, Ladetto M, Ferrero S, Rossi A, Barbui AM, Patti C, Costa A, Vitolo U, Chiappella A, Benedetti F, Ferreri AJM, Nicoli P, Rigacci L, Castellino C, Gianni AM, Rambaldi A, Tarella C. Upfront intensive chemo-immunotherapy with autograft in 199 adult mantle cell lymphoma patients: prolonged survival and cure potentiality at long term. *Bone Marrow Transplant*. 2021 Jul 7. doi: 10.1038/s41409-021-01391
281. Advani R, Skrypets T, Civallero M, Spinner MA, Manni M, Kim W, Shustov A, Horwitz SM, Hitz F, Cabrera ME, Dlouhy I, Vassallo J, Pileri SA, Inghirami GG, Montoto S, Vitolo U, Radford J, Vose J, Federico M. Outcomes and Prognostic Factors in Angioimmunoblastic T cell Lymphoma: Final Report from the International TCell Project *Blood*. 2021 Mar 30: blood.2020010387
282. Rossi A, Orecchioni S, Falvo P, Tabanelli V, Baiardi E, Agostinelli C, Melle F, Motta G, Calleri A, Fiori S, Corsini C, Casadei B, Mazzara S, Vitolo U, Bertolini F, Zinzani PL, Alcalay M, Pelicci PG, Pileri S, Tarella C, Derenzini E. Dual targeting of the DNA damage response pathway and BCL-2 in diffuse large B-cell lymphoma. *Leukemia*. 2021 Jul 24. doi: 10.1038/s41375-021-01347-6
283. Strefford JC, Nowicka M, Hargreaves CE, Burton C, Davies A, Ganderton R, Hiddemann W, Iriyama C, Klapper W, Latham KV, Martelli M, Mir F, Parker H, Potter KN, Rose-Zerilli MJ, Sehn LH, Trněný M, Vitolo U, Bolen CR, Klein C, Knapp A, Oestergaard MZ, Cragg MS. Single-nucleotide Fcγ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma. *Blood Adv*. 2021 Aug 10;5(15):2935-2944. doi: 10.1182/bloodadvances.2020003985.
284. Nowicka M, Hilton LK, Ashton-Key M, Hargreaves CE, Lee C, Foxall R, Carter MJ, Beers SA, Potter KN, Bolen CR, Klein C, Knapp A, Mir F, Rose-Zerilli M, Burton C, Klapper W, Scott DW, Sehn LH, Vitolo U, Martelli M, Trněný M, Rushton CK, Slack GW, Farinha P, Strefford JC, Oestergaard MZ, Morin RD, Cragg

- MS. Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatment. *Blood Adv.* 2021 Aug 10;5(15):2945-2957. doi: 10.1182/bloodadvances.2021004770.
285. Kostakoglu L, Mattiello F, Martelli M, Sehn LH, Belada D, Ghiggi C, Chua N, González-Barca E, Hong X, Pinto A, Shi Y, Tatsumi Y, Bolen C, Knapp A, Sellam G, Nielsen T, Sahin D, Vitolo U, Trněný M. Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA study. *Haematologica.* 2021 Aug 19. doi: 10.3324/haematol.2021.278663.
286. Casulo C, Dixon JG, Le-Rademacher J, Hoster E, Hochster H, Hiddemann W, Marcus RE, Kimby EK, Herold M, Sebban CJ, Gyan E, Foon KA, Nielsen TG, Vitolo U, Salles GA, Shi Q, Flowers CR. Validation of POD24 As a Robust Early Clinical Endpoint of Poor Survival in FL from 5,225 Patients on 13 Clinical Trials. *Blood.* 2021 Oct 6;blood.2020010263. doi: 10.1182/blood.2020010263. Online ahead of print.
287. Bonfiglio F, Bruscatto A, Guidetti F, Terzi di Bergamo L, Faderl MR, Spina V, Condoluci A, Bonomini L, Forestieri G, Koch R, Piffaretti D, Pini K, Piroso MC, Cittone MG, Arribas A, Lucioni M, Ghilardi G, Wu W, Arcaini L, Baptista MJ, Bastidas G, Beà S, Boldorini R, Broccoli A, Bühler MM, Canzonieri V, Cascione L, Ceriani L, Cogliatti SB, Corradini P, Derenzini E, Devizzi L, Dietrich S, Elia AR, Facchetti F, Gaidano G, Garcia JF, Gerber B, Ghia P, Gomes da Silva M, Gritti G, Guidetti A, Hitz F, Inghirami GG, Ladetto M, López-Guillermo A, Lucchini E, Maiorana A, Marasca R, Matutes E, Meignin V, Merli M, Moccia AA, Mollejo M, Montalban C, Novak U, Oscier DG, Passamonti F, Piazza FA, Pizzolitto S, Rambaldi A, Sabattini E, Salles GA, Santambrogio E, Scarfo L, Stathis A, Stussi G, Geyer JT, Tapia G, Tarella C, Thieblemont C, Tousseyn T, Tucci A, Vanini G, Visco C, Vitolo U, Walewska R, Zaja F, Zenz T, Zinzani PL, Khiabanian H, Calcinotto A, Bertoni F, Bhagat G, Campo E, de Leval L, Dirnhofer S, Pileri SA, Piris MA, Traverse-Glehen A, Tzankov A, Paulli M, Ponzoni M, Mazzucchelli L, Cavalli F, Zucca E, Rossi D. Genetic and Phenotypic Attributes of Splenic Marginal Zone Lymphoma. *Blood.* 2021 Oct 15;blood.2021012386. doi: 10.1182/blood.2021012386. Online ahead of print.
288. Chiappella A, Diop F, Agostinelli C, Novo M, Nassi L, Evangelista A, Ciccone G, Di Rocco A, Martelli M, Melle F, Moia R, Motta G, Righi S, Santambrogio E, Tucci A, Balzarotti M, Ladetto M, Pileri SA, Gaidano G, Vitolo U; Fondazione Italiana Linfomi (FIL) Prognostic impact of TP53 mutation in newly diagnosed diffuse large B-cell lymphoma patients treated in the FIL-DLCL04 trial. *Br J Haematol.* 2021 Dec 23. doi: 10.1111/bjh.17971. Online ahead of print.
289. Zaccaria GM, Ferrero S, Hoster E, Passera R, Evangelista A, Genuardi E, Drandi D, Ghislieri M, Barbero D, Del Giudice I, Tani M, Moia R, Volpetti S, Cabras MG, Di Renzo N, Merli F, Vallisa D, Spina M, Pascarella A, Latte G, Patti C, Fabbri A, Guarini A, Vitolo U, Hermine O, Kluin-Nelemans HC, Cortelazzo S, Dreyling M, Ladetto M. A Clinical Prognostic Model Based on Machine Learning from the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial. *Cancers (Basel).* 2021 Dec 31;14(1):188. doi: 10.3390/cancers14010188. PMID: 35008361
290. Vitolo U, Novo M. Frontline chemotherapy-free induction for mantle cell lymphoma. *Lancet Oncol.* 2022 Mar; 23(3):321-322. doi: 10.1016/S1470-2045(21)00721-X. Epub 2022 Jan 21.
291. Younes A, Burke JM, Diefenbach CS, Ferrari S, Khan C, Sharman JP, Tani M, Ujjani C, Vitolo U, Yuen SLS, Raval A, Shivhare M, Nielsen TG, Sellam G, Gilbertson M. Safety and efficacy of atezolizumab with obinutuzumab and bendamustine in previously untreated follicular lymphoma *Blood Adv.* 2022 Mar 31;bloodadvances.2021006131. doi: 10.1182/bloodadvances.2021006131. Online ahead of print.
292. Ruiz IC, Martelli M, Sehn LH, Vitolo U, Nielsen TG, Sellam G, Bottos A, Klingbiel D, Kostakoglu L. Baseline Total Metabolic Tumor Volume is Prognostic for Refractoriness to Immunochemotherapy in DLBCL: Results From GOYA. *Clin Lymphoma Myeloma Leuk.* 2022 Aug;22(8):e804-e814. doi: 10.1016/j.clml.2022.04.010. Epub 2022 Apr 14.
293. Wang ML, Jurczak W, Jerkeman M, Trotman J, Zinzani PL, Belada D, Boccomini C, Flinn IW, Giri P, Goy A, Hamlin PA, Hermine O, Hernández-Rivas JÁ, Hong X, Kim SJ, Lewis D, Mishima Y, Özcan M, Perini GF, Pocock C, Song Y, Spurgeon SE, Storrington JM, Walewski J, Zhu J, Qin R, Henninger T, Deshpande S, Howes

- A, Le Gouill S, Dreyling M; SHINE Investigators. Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma *N Engl J Med.* 2022 Jun 30;386(26):2482-2494. doi: 10.1056/NEJMoa2201817. Epub 2022 Jun 3.
294. Tabanelli V, Melle F, Motta G, Mazzara S, Fabbri M, Agostinelli C, Calleri A, Del Corvo M, Fiori S, Lorenzini D, Cesano A, Chiappella A, Vitolo U, Derenzini E, Griffin GK, Rodig SJ, Vanazzi A, Sabattini E, Tarella C, Sapienza MR, Pileri SA. The identification of TCF1+ progenitor exhausted T cells in THRLBCL may predict a better response to PD-1/PD-L1 blockade. *Blood Adv.* 2022 Aug 9;6(15):4634-4644. doi: 10.1182/bloodadvances.2022007046.
295. Broglio K, Kostakoglu L, Ward C, Mattiello F, Sahin D, Nielsen T, McGlothlin A, Elliott CF, Witzig T, Sehn LH, Trněný M, Vitolo U, Martelli M, Foster M, Wendelberger B, Nowakowski G, Berry DA. PET-CR as a potential surrogate endpoint in untreated DLBCL: meta-analysis and implications for clinical trial design *Leuk Lymphoma.* 2022 Jul 11:1-16. doi: 10.1080/10428194.2022.2095624. Online ahead of print
296. Kostakoglu L, Dalmasso F, Berchiolla P, Pierce LA, Vitolo U, Martelli M, Sehn LH, Trněný M, Nielsen TG, Bolen CR, Sahin D, Lee C, El-Galaly TC, Mattiello F, Kinahan PE, Chauvie S. *EJHaem.* A prognostic model integrating PET-derived metrics and image texture analyses with clinical risk factors from GOYA2022 *Mar 24;3(2):406-414.* doi: 10.1002/jha2.421. eCollection 2022 May.
297. Vegliante MC, Mazzara S, Zaccaria GM, De Summa S, Esposito F, Melle F, Motta G, Sapienza MR, Opinto G, Volpe G, Bucci A, Gargano G, Enjuanes A, Tabanelli V, Fiori S, Minoia C, Clemente F, Negri A, Gulino A, Morello G, Scattone A, Zito AF, Tommasi S, Agostinelli C, Vitolo U, Chiappella A, Barbui AM, Derenzini E, Zinzani PL, Casadei B, Rivas-Delgado A, López-Guillermo A, Campo E, Moschetta A, Guarini A, Pileri SA, Ciavarella S. NR1H3 (LXR α) is associated with pro-inflammatory macrophages, predicts survival and suggests potential therapeutic rationales in diffuse large b-cell lymphoma. *Hematol Oncol.* 2022 Jul 18. doi: 10.1002/hon.3050. Online ahead of print.
298. Davies A, Kater AP, Sharman JP, Stilgenbauer S, Vitolo U, Klein C, Parreira J, Salles G. Obinutuzumab in the treatment of B-cell malignancies: a comprehensive review. *Future Oncol.* 2022 Aug;18(26):2943-2966. doi: 10.2217/fon-2022-0112. Epub 2022 Jul 20.
299. Poletto S, Novo M, Paruzzo L, Frascione PMM, Vitolo U. Treatment strategies for patients with diffuse large B-cell lymphoma. *Cancer Treat Rev.* 2022 Jul 31;110:102443. doi: 10.1016/j.ctrv.2022.102443. Online ahead of print.
300. Thieblemont C, Chartier L, Duhrsen U, Vitolo U, Barrington S, Zaucha JM, Vercellino L, Gomes da Silva M, Patrocinio-Carvalho I, Decazes P, Viailly PJ, Tilly H, Berriolo-Riedinger A, Casasnovas O, Hüttmann A, Ilyas H, Mikhael NG, Dunn JT, Cottreau AS, Schmitz C, Kostakoglu L, Paulson JN, Nielsen TG, Meignan M. A tumor volume and performance status model to predict outcome prior to treatment in diffuse large B-cell lymphoma. *Blood Adv.* 2022 Aug 31;bloodadvances.2021006923. doi: 10.1182/bloodadvances.2021006923. Online ahead of print.
301. Vitolo U, Nowakowski GS, Burke JM, Fox CP, Trneny M, Chiappella A, Waldron-Lynch M, Hadar N, Pachori A, Lenz G. ABCL-023 frontMIND: A Phase III, Randomized, Double-Blind Study of Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP Alone for Newly Diagnosed High-Intermediate and High-Risk Diffuse Large B-Cell Lymphoma. *Clin Lymphoma Myeloma Leuk.* 2022 Oct;22 Suppl 2:S352-S353. doi: 10.1016/S2152-2650(22)01488-4.
302. Younes A, Burke JM, Cheson BD, Diefenbach C, Ferrari S, Hahn U, Hawkes EA, Khan C, Lossos IS, Musuraca G, Tani M, Vitolo U, Yuen SLS, Raval A, Shivhare M, Nielsen TG, Sellam G, Sharman JP. Safety and efficacy of atezolizumab with rituximab and CHOP in previously untreated diffuse large B-cell lymphoma. *Blood Adv.* 2022 Oct 26;bloodadvances.2022008344. doi: 10.1182/bloodadvances.2022008344.
303. Nizzoli ME, Manni M, Ghiggi C, Pulsoni A, Musuraca G, Merli M, Califano C, Bari A, Massaia M, Conconi A, Musto P, Mannina D, Perrone T, Re F, Galimberti S, Gini G, Capponi M, Vitolo U, Usai SV, Stefani PM, Ballerini F, Liberati AM, Pennese E, Pastore D, Skrypets T, Catellani H, Marcheselli L, Federico M, Luminari S. Impact of immunochemotherapy with R-bendamustine or R-CHOP for treatment naïve advanced-stage follicular lymphoma: A subset analysis of the FOLL12 trial by Fondazione Italiana Linfomi *Hematol Oncol.* 2023 Oct;41(4):655-662. doi: 10.1002/hon.3184. Epub 2023 May 28.

304. Vitolo U, Frascione PMM, Bonello F. Pola-R-CHP for frontline therapy in DLBCL: Are we saving money by spending more? *Br J Haematol.* 2023 Aug;202(4):731-733. doi: 10.1111/bjh.18934. Epub 2023 Jun 14.
305. Lupia T, Crisà E, Gaviraghi A, Rizzello B, Di Vincenzo A, Carnevale-Schianca F, Caravelli D, Fizzotti M, Tolomeo F, Vitolo U, De Benedetto I, Shbaklo N, Cerutti A, Fenu P, Gregorc V, Corcione S, Ghisetti V, De Rosa FG. Strongyloides spp. and Cytomegalovirus Co-Infection in Patient Affected by Non-Hodgkin Lymphoma. *Trop Med Infect Dis.* 2023 Jun 20;8(6):331. doi: 10.3390/tropicalmed8060331.
306. Lupia T, Crisà E, Gaviraghi A, Rizzello B, Di Vincenzo A, Carnevale-Schianca F, Caravelli D, Fizzotti M, Tolomeo F, Vitolo U, De Benedetto I, Shbaklo N, Cerutti A, Fenu P, Gregorc V, Corcione S, Ghisetti V, De Rosa FG. Overlapping Infection by Strongyloides spp. and Cytomegalovirus in the Immunocompromised Host: A Comprehensive Review of the Literature *Trop Med Infect Dis.* 2023 Jul 10;8(7):358. doi: 10.3390/tropicalmed8070358.
307. Vitolo U, Chiappella A. A new frontier for R-CHOP: is two better than one? *Blood.* 2023 Oct 19;142(16):1331-1332. doi: 10.1182/blood.2023021521.
308. Ladetto M, Tavarozzi R, Zanni M, Evangelista A, Ferrero S, Tucci A, Botto B, Bolis S, Volpetti S, Zilioli VR, Puccini B, Arcari A, Pavone V, Gaidano G, Corradini P, Tani M, Cavallo F, Milone G, Ghiggi C, Pinto A, Pastore D, Ferreri AJM, Latte G, Patti C, Re F, Benedetti F, Luminari S, Pennese E, Bossi E, Boccomini C, Anastasia A, Bottelli C, Ciccone G, Vitolo U. Radioimmunotherapy versus autologous hematopoietic stem cell transplantation in relapsed/refractory follicular lymphoma: a Fondazione Italiana Linfomi multicenter, randomized, phase III trial. *Ann Oncol.* 2023 Nov 3:S0923-7534(23)04240-0. doi: 10.1016/j.annonc.2023.10.095.
309. Kostakoglu L, Martelli M, Sehn LH, Davies A, Trněný M, Herold M, Vitolo U, Hiddemann W, Trotman J, Knapp A, Mattiello F, Nielsen TG, Sahin D, Sellam G, Ward C, Younes A. A comparison of the prognostic performance of the Lugano 2014 and RECIL 2017 response criteria in patients with NHL from the phase III GOYA and GALLIUM trials. *EJHaem.* 2023 Oct 9;4(4):1042-1051. doi: 10.1002/jha2.796. eCollection 2023 Nov.
310. Conconi A, Chiappella A, Ferreri AJ, Stathis A, Botto B, Sassone M, Gaidano G, Balzarotti M MD, Merli F, Tucci A, Vanazzi A, Tani M, Bruna R, Orsucci L, Cabras MG, Celli M, Annibaldi O, Liberati AM, Zanni M, Ghiggi C, Pisani F, Pinotti G, Dore F, Esposito F, Piroso MC, Cesaretti M, Bonomini L, Vitolo U, Zucca E. IELSG30 phase 2 trial: intravenous and intrathecal CNS prophylaxis in primary testicular diffuse large B-cell lymphoma. *Blood Adv.* 2024 Jan 4:bloodadvances.2023011251. doi: 10.1182/bloodadvances.2023011251.

Candiolo January 31 2024

